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1. Summary  
Risk Factors for positive surgical margins in organ-confined prostate cancer treated with 
robotic-assisted Radical Prostatectomy 
 
Prostate cancer is said to be the leading cause of solid neoplasms in males in Europe. Over the 
last two decades the screening for and diagnosis of prostate cancer, especially organ-confined 
prostate cancer, has increased dramatically, predominantly due to patient awareness and the 
introduction of prostate specific antigen (PSA) screening. This has also prompted the use of 
new treatment techniques, especially in minimally invasive surgeries, amongst which the 
robotic-assisted radical prostatectomy has found its place. 
 
Organ-confined prostate cancer in patients with a life expectancy of more than 10 years should 
be treated curatively via surgical removal or various radiotherapy modalities.  
 
The goal of the radical prostatectomy is to remove the entire prostate and the seminal vesicles, 
while at the same time attempting to preserve continence and erectile function.  The surgery 
requires a fine balance between dissecting as close as possible to the prostate capsule in order 
to preserve the neurovascular bundle responsible for erectile function, but at the same time 
dissecting sufficiently far away from the tumour to avoid positive surgical margins. Besides 
lymph node dissection, the absence of a positive surgical margin is the only prognostic factor 
upon which the surgeon may have an impact. 
 
The aim of this thesis is to evaluate the factors that influence the positive surgical margin rate.  
 
The first 1200 patients who had undergone a robotic-assisted radical prostatectomy at the 
Department of Urology of the University Clinic of Saarland made up the study population of this 
research. Data capturing commenced in March 2006 when the robotic-assisted radical 
prostatectomy was introduced at the Department. Patient information, including data retrieved 
retrospectively, was saved in a central database. Additional data sets were added to the 
collection over time. From April 2010 onwards the “da Vinci Worksheet” was implemented as a 
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patient data capturing process during the preoperative and intrahospital periods. This 
worksheet was to be completed by the treating doctors. At the end of 2010 an audit was 
initiated in order to complete any missing data. Certain variables were identified as being 
relevant in the identification of risk factors for positive surgical margins in organ-confined 
disease. With the assistance of the Institute for Medical Biometry, Epidemiology and Medical 
Informatics of the University Clinic of Saarland, SPSS was used to determine the Fisher Exact 
Test, as well as the Cox Regression Model. 
 
In total, 857 patients had organ-confined disease, of which 7,9% (n=68) had positive surgical 
margins. In our analysis there was a statistically significant increase in positive surgical margins 
when a nerve-sparing operation had been performed.  A statistically significant increase could 
also be shown in bilateral nerve-sparing operations when compared to unilateral nerve-sparing 
operations. Of note was that a prostate weight of below 35g was related to a higher incidence 
of positive surgical margins. This was also statistically significant when examining patients who 
had a low prostate weight and a nerve-sparing operation (19.3% vs 8.6% p=0.009).  
 
The learning curve across the 1200 patients showed a statistically significant decline in the 
positive surgical margin rate. This was also seen when only examining the nerve-sparing 
operations as the rate declined from 14.7% in the first 400 patients to 5.4% in the last 400 
patients (p=0.011) Furthermore, when the preoperative biopsies of the prostate were 
‘inadequate’ a statistically significant increase in the positive surgical margin rate was found. 
(‘Adequate’ biopsies entail the removal of eight or more biopsy cores and the identification of 
the location of the cancer).  
 
The Cox Regression Model was used to identify independent risk factors. The two variables that 
remained statistically significant in the multivariable analysis were the presence of a nerve-
sparing operation (p=0.003) and a low prostate weight (p=0.022). 
 
In conclusion it can be stated that the two independent risk factors for positive surgical margins 
in patients with organ-confined prostate cancer undergoing a robotic-assisted radical 
prostatectomy, are a low prostate weight of less than 35g and a nerve-sparing operation. 
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1. Zusammenfassung 
Risikofaktoren für positive chirurgische Schnittränder bei Roboter- assistierter radikaler 
Prostatektomie bei organbegrenztem Prostatakarzinom 
 
Das Prostatakarzinom ist die häufigste maligne Tumorerkrankung des Mannes in Europa. 
Während der letzten 20 Jahre ist die Inzidenz des Prostatakarzinoms aufgrund einer besseren 
gesundheitlichen Aufklärung und dem zunehmenden Einsatz des PSA-Screening deutlich 
angestiegen. Heutzutage werden vor allem organbegrenzte Prostatakarzinome diagnostiziert. 
Dies hat auch die Entwicklung neuerer operativer Methoden wie die roboter-assisterte radikale 
Prostatektomie beeinflusst, einer Weiterentwicklung der minimal-invasiven laparoskopischen 
Operationsverfahren.    
 
Bei Patienten mit einem organbegrenzem Prostatakarzinom und einer Lebenserwartung von 
mehr als 10 Jahren sollte ein kurativer Therapieansatz gewählt werden. Als Standardtherapie 
stehen die radikale Prostatektomie und verschiedenen strahlentherapeutische Verfahren zur 
Verfügung. Bei der radikalen Prostatektomie gilt es, neben dem bestmöglichen onkologischen 
Ergebnis mit kompletter Entfernung der tumortragenden Prostata und Samenbläschen auch 
den Erhalt der Lebensqualität zu gewährleisten, vor allem im Hinblick auf die Kontinenz und 
erektile Funktion. Der Operateur steht vor der Aufgabe, das Gefäß-Nerven-Bündel für die 
erektile Funktion zu schonen, welches dicht an der Prostatakapsel verläuft, ohne gleichzeitig 
positive chirurgische Schnittränder zu provozieren. Positive Schnittränder gelten als 
prognostische Faktoren für eine schlechtere Prognose und stellen damit den einzigen 
prognostische Faktor dar, der vom Operateur mit beeinflusst werden kann.  
 
Ziel dieser Arbeit war es daher, mögliche Einflussfaktoren für einen positiven chirurgischen 
Schnitträndern, dem sogenannten R1-Status, zu identifizieren. 
 
Die Daten der ersten 1200 Patienten wurden ausgewertet, die sich einer roboter-assistierten 
radikalen Prostatektomie an der Klinik für Urologie und Kinderurologie am Universitätsklinikum 
des Saarlandes unterzogen haben. Die prospektive Datenerhebung begann im März 2006 mit 
Einführung der roboter-assistierten radikale Prostatektomie . Im Laufe der Zeit erweiterten sich 
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die abgefragten Parameter und die Daten der ersten Patienten wurden dann retrospektiv in der 
zentralen Datenbank nachgetragen. Seit April 2010 wurde zur besseren Dokumentation der 
sog. “da Vinci Laufzettel” eingeführt. Der Laufzettel begleitet den Patienten während des 
gesamten Aufenthalt und wird durch die jeweils behandelnden Ärzte geführt. Im Dezember 
2010 wurden die Datensätze auf Konsistenz und Vollständigkeit hin überprüft. Mit 
Unterstützung des Instituts für Medizinische Biometrie, Epidemiologie und Medizinische 
Informatik wurden einzelne Faktoren ausgewählt und statistisch geprüft, die für den R1 Status 
wichtig sein könnten. Diese Auswertung erfolgte mit SPSS. Der Fisher Exact Test wie auch das 
Cox Regression Model wurden angewandt. 
 
Insgesamt wurden 857 Patienten mit einem organbegrenzten Prostatakarzinom identifiziert, 
7,9% (n= 68) dieser Patienten hatten einen R1-Status. Mehrere verschiedene Faktoren wurden 
nach einer Literaturrecherche identifiziert und untersucht. Eine statistische signifikante 
Zunahme in der R1 Rate wurde bei einer nerverhaltenden Operation festgestellt, wobei ein 
signifikant höherer R-1 Status bei einem beidseitigem gegenüber einem einseitigen Nerverhalt 
festgestellt wurde. Ein weiterer Prognosefaktor für einen R1-Status war das Prostatagewicht 
unter 35g gegenüber >35g. Dieser war auch statistisch relevant bei einer nerverhaltende 
Operation (19.3% und 8.6% p=0.009). Die Analyse der Lernkurve fand eine statische signifikante 
Abnahme der R1 Rate bei organ-begrenzten Tumoren im zeitlichen Verlauf. Die Patienten mit 
einer nerverhaltenden Operation zeigten auch eine statische signifikante Abnahme von initial 
14.7% bei den ersten 400 auf 5.4% bei den letzten 400 Patienten (p=0.011). Eine mangelnde 
Qualität des präoperativen Stanzbiopsiebefundes führt ebenfalls zu einer statistisch signifikant 
höheren R1-Rate, wobei eine ausreichende Qualität bei einer Anzahl der Stanzbiopsien ≥8 und 
dem Vorhandensein einer Seitenangabe für die positiven Stanzen gegeben wurde.  
In der multivariaten Cox Regressions-Analyse konnten dann die nerverhaltende Operation 
(p=0.003) sowie ein Prostatagewicht <35g (p=0.022) als unabhängige Risikofaktoren für einen 
R1 Status identifiziert werden. 
 
Zusammenfassend zeigt sich, dass Patienten mit nerverhaltender Operation und einem 
Prostatagewicht <35g ein signifikant erhöhtes Risiko für das Auftreten eines R1-Befundes 
aufweisen.  
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2. Introduction 
2.1 The Incidence and Aetiology of Prostate Cancer 
 
Ever since the prostate was first described, presumably, by Heròphilus in 300BC (1) it has been 
an organ of much interest in the urological society especially with regard to the benign 
enlargement of the prostate and prostate cancer.  
 
Prostate cancer is the most common non-cutaneous malignancy in men (2) with the incidence 
in Europe being 87.2/100000. In Germany in 1998, 18.7% of all newly diagnosed malignancies 
were prostate cancers.(3) In the USA, the estimated lifetime risk of prostate cancer is 16.72% 
with the lifetime risk of mortality being 2.57%.  The incidence increases with age and black 
African-Americans have a higher incidence than white Americans.(4) Scandinavian countries 
have a particularly high incidence and far eastern countries have a relatively low incidence.(3) 
The European mortality due to prostate cancer currently lies at 34.1/100000. In a recent article 
published by Heidenreich et al prostate cancer was said to be becoming the leading solid 
neoplasm in Europe, with a 15% incidence in developed countries and a 4% incidence in 
developing countries.(5)  
 
The aetiology of prostate cancer is not yet understood. There is a genetic predisposition in 
some families, as one can demonstrate a relative risk increase according to the number of 
affected family members.(6) Familial prostate cancers usually have an earlier onset, 
predominantly under the age of 55 years.(3) As with breast cancer, carriers of the gene BRCA1 
and BRCA2 have an increased risk of prostate cancer (7) and recently there has been a great 
focus on the hereditary prostate cancer-1 gene (HPC1).(8) Other contributing factors to the 
development of prostate cancer are an over expression of telomerase as well as a deficiency in 
Glutathion-S-transferase. Genes have also been implicated in prostatic carcinogenesis, such as a 
mutation of p53, vascular endothelial growth factor and a loss of E-Cadherin, to mention a few. 
Genes such as myc-oncogens and p27 have been attributed to the progression and metastases 
of prostate cancer.  Numerous other enzymes, receptors and growth factors have been linked 
to the development of the cancer e.g. 5α-reductase-type 2 and insulin-like growth factor 1.(3) 
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The development of prostate cancer has also been blamed on nutrition, where the nutrition 
theory links certain diets in some populations to a predisposition to this type of cancer. The 
ingestion of animal fats, common in the western diet, may also explain the increased incidence 
of prostate cancer in the western world.(9) At the same time, tomatoes may be cancer-
protective, whereas raised calcium levels may be carcinogenic.(3) In populations previously 
classified as “low risk populations”, an increase in prostate cancer was seen after immigrating 
to a Scandinavian country, Sweden, demonstrating the importance of environmental and 
possibly dietary factors.(10) There have also been proven associations between obesity and 
prostate cancer.(11)  
 
The hormonal influences on prostate cancer can also not be ignored. Prostate cancer does not 
occur in males castrated before puberty and hormone deprivation is also a form of treatment in 
prostate cancer.(2, 3) 
 
The detection, treatment and mortality rates of prostate cancer have dramatically changed, 
and are continuously changing, since the introduction of prostate specific antigen (PSA) 
screening, which has increased the detection rate and survival of patients in Europe and the 
United States, particularly amongst patients aged above 75 years.(12) None the less, due to the 
very high incidence in the male population and especially when the longer life expectancy in 
our population is considered, prostate cancer still remains a hot topic amongst medical 
personnel and researchers.  
 
2.2 The Anatomy of the Prostate 
 
In order to facilitate further discussions involving surgical techniques used in the treatment of 
prostate cancer, a short summary of the anatomy of the prostate has been drafted below.  
 
The role of the prostate is to add prostatic secretions to the bulk of the fluid during ejaculation. 
The prostatic gland secretes a thin, milky fluid that contains calcium, citrate ion, phosphate ion, 
a clotting enzyme and profibrinolysin. The slightly alkaline characteristics of the fluid are very 
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important since sperm do not become optimally motile until the pH of the surrounding fluids 
rises to about 6.0 -6.5.(13) 
 
The prostate is a walnut-sized gland situated at the base of the bladder. In a young male the 
gland weighs about 20g, but is known to enlarge over time. Certain anatomical landmarks are 
very important: The apex is the most inferior part of the gland and the base of the prostate is 
the superior part of the gland. The prostate lobes are found on either side of the prostatic 
urethra, which transverses the prostate. The prostatic urethra is found in the anterior part of 
the gland and is covered with urothelium. The urethra forms a more or less 30° angle anteriorly 
in the middle of the prostate and the verumontanum is just distal to this angulation.(2,14) 
 
 
 
 
 
 
 
 
 
             (Drawing. K-W. Bütow 2013) 
Figure 1: The Prostate and Seminal Vesicles  
 
The prostate is divided into different zones and lobes and is enclosed in a capsule made of 
collagen, elastin and smooth muscle.(2,14) 
 
The central zone is a cone shaped area that surrounds the ejaculatory duct and extends from 
the base of the bladder to the verumontanum. Only 1-5% of all prostate cancers develop in this 
zone. The peripheral zone is found posteriolaterally in the prostate and also contains the most 
prostatic glandular tissue. Up to 70% of all adenocarcinomas of the prostate develop in this 
zone. The transitional zone surrounds the prostatic urethra proximal to the verumontanum. 
Approximately 20% of cancers arise from this area. The prostate lobes are described as lateral 
A = Ampulla 
ED = Ejaculatory Duct 
I = Isthmus 
P = Prostate 
SV = Seminal Vesicle 
VD = Vas Deferens 
U = Urethra 
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and median. Enlarged periurethral tissue in the transitional zone causes hyperplasia of the 
lateral lobes. The hyperplastic periurethral glands bulge into the bladder neck and form a 
median lobe.(2, 14, 15) 
 
 
 
 
 
 
 
 
 
 
                 (Drawing. K-W. Bütow 2013) 
Figure 2: Schematic Representation of the zonal Anatomy  
 
The bladder and bladder neck are situated superior to the prostate and in relation to the base 
of the prostate. Posterior and superior to the prostate are the seminal vesicles, which are 
accompanied by the ductus deferens, a continuation of the duct of the epididymis. Posterior to 
the prostate is the rectoprostatic fascia (Denonvilliers fascia), which lies between the prostate 
and the rectum. The urethral sphincter, consisting of striated muscle, is in continuation with the 
apex of the prostate and is found at the inferior border of the gland. On both lateral aspects of 
the prostate the neurovascular bundle is situated which contains the nerves derived from the 
pelvic plexus. Posterior to the pubic symphysis is retropubic space and the deep venous plexus. 
The prostate is connected to the pubic bone via the puboprostatic ligament, a continuation of 
the prostatic sheath.(16) The prostate’s main blood supply is derived from the inferior vesicle 
artery, which originates from the anterior division of iliac artery. The inferior vesicle artery then 
divides into two main branches, which run between the layers of the lateral prostatic fascia. 
One of the arteries, the capsular artery continues posteriolaterally to the prostate with the 
cavernous nerves. The deep dorsal vein collects the venous drainage of the prostate and finally 
           ED = Ejaculatory Duct 
SV = Seminal Vesicle 
U = Urethra 
 
V = Verumontanum 
cz = central zone 
tz = transitional zone 
pz = peripheral zone 
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drains into the dorsal venous plexus, which joins the lateral venous plexus. These all eventually 
drain by means of the pudendal, obturator and vesicle plexus into the internal iliac vein.(14, 16) 
 
 
 
 
 
 
 
 
 
 
  
           
(Drawing. K-W. Bütow 2013) 
Figure 3. A cross-section of the male reproductive tract 
 
2.3 Prostate Cancer Screening and Diagnosis 
 
Prostate cancer screening usually compromises of two elements: The digital rectal examination 
and since the 1990’s is the serum PSA level. According to two large randomized trials, namely 
the Prostate, Lung, Colorectal, and Ovary trail (PLCO) in the United States and the European 
Randomised Study of Screening for Prostate Cancer (ERSPC) trail in Europe, there is currently no 
evidence that widespread screening of the population for the detection of early prostate cancer 
is required.(17,18) This said, in most developed countries, prostate cancer screening 
commences from about the age of 45 years. The American Urological Association (AUA), 
Japanese Urological Association (JUA), and National Comprehensive Cancer Network (NCCN) 
recommend that all men obtain a baseline PSA at age 40.(19) 
 
As previously mentioned most prostate cancers are located in the peripheral zone of the 
prostate and can be detected by digital rectal examination if they are larger than 0,2ml in 
 
 
 
A = Anus 
 
B = Bladder 
 
E = Epididymis 
PE = Penis 
 
PR = Prostate 
S = Scrotum 
 
SV = Seminal Vesicle 
T = Testis 
 
TV = Tunica Vaginalis 
U = Urethra 
 
VD = Vas Deferens 
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volume.(20) If there is a suspicious finding on the digital rectal examination, then a further 
investigation in the form of a prostate biopsy is necessary. Even where the PSA value is within 
the normal range, a suspicious digital rectal examination alone has a positive predictive value of 
5-30%.(21) In a recent study conducted by Abdrabo et al., the digital rectal examination alone 
had a 63,8% sensitivity and a 68% specificity for detecting prostate cancer.(22) 
 
The other powerful tool used in the screening of prostate cancer is the PSA enzyme, which 
liquefies coagulated ejaculate, necessary for reproduction. An elevated PSA is specific to the 
prostate but may be due to numerous causes, such as prostatitis, benign prostatic hyperplasia 
or prostate cancer.(23) Unfortunately no PSA value is specific for the diagnosis of prostate 
cancer, but as a general rule a PSA value of above 4ng/ml should be regarded as suspicious. This 
value often however needs to be adjusted according to age and prostate volume. Between 65% 
to 90% of the total PSA (tPSA) is bound (cPSA) and only 10% to 35% of PSA is free PSA (fPSA). In 
some cases the free/total PSA ratio is used to try and differentiate between benign 
enlargement of the prostate and prostate cancer.(24) Research has been conducted on other 
parameters such as PSA density, PSA density in the transitional zone, age specific reference 
ranges, PSA velocity and free PSA, but the gold standard still remains the serum PSA.(3) PSA is a 
continuous parameter; the higher the value, the more likely it is due to prostate cancer. An 
elevated PSA level is a better predictor of prostate cancer than a digital rectal examination. A 
2004 study in the USA revealed that some men may harbour prostate cancer at even low levels 
of serum PSA.(20)  
 
Table 1. PSA Risk 
PSA level  
(ng/ml) 
Risk of PCa 
0-0.5 6.6% 
0.6-1 10.1% 
1.1-2 17.0% 
2.1-3 23.9% 
3.1-4 26.9% 
Heidenreich et al.(20) 
 
14 
It can therefore be said that there is no optimal PSA threshold value for detecting prostate 
cancers.(25) 
 
Once the digital rectal examination, PSA level and the therapeutic consequence indicate that 
further investigations are required, a biopsy of the prostate is done. Most prostate biopsies are 
guided by transrectal ultrasound, although some urologists prefer to do perineal prostate 
biopsies. In the past, a sextant biopsy was considered to be the gold standard, however, 
according to the latest research, if the prostate volume is 30-40ml, at least eight cores should 
be sampled. Extra sampling of a suspect lesion on transrectal ultrasound is also suggested.(20) 
In a prospective study, Presti et al. found that by using the traditional sextant biopsy, 20% of 
cancers were missed, but by doing an eight core biopsy (apex, mid lobar mid gland, lateral mid 
gland and lateral base) the cancer detection rate went up to 95%. This was irrespective of 
prostate size.(26) 
 
2.4 Histopathology of Prostate Cancer 
 
In the majority of cases the prostatic tumour is an adenocarcinoma that is well differentiated, 
forming an acini, tubules or cribiform pattern. The neoplastic acini invade the stroma of the 
gland as well as the lymphatics and occasionally the perineural areas.(27) Like most tumours, 
prostate cancer is defined according to the TNM classification designed by the Union of 
International Cancer Control (UICC).(28)  
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Table 2. The TNM classification: 
 Primary Tumour 
T1 Clinically in apparent tumour  
T1a Incidental finding, less than 5% burden on transurethral resection  
T1b Incidental finding, more than 5% burden on transurethral resection 
T1c Diagnosis on prostate biopsy, no tumour found on final histology 
T2 Tumour confined to prostate 
T2a Tumour in less than 50% of a single prostate lobe 
T2b Tumour in more than 50% of a single prostate lobe 
T2c Tumour present in both lobes 
T3 Tumour extends beyond prostate capsule 
T3a Extracapsular extension with bladder neck involvement 
T3b Involvement of the seminal vesicles 
T4 Tumour is fixed or invades other structures besides the seminal vesicles 
  
 Regional Lymph Nodes 
N0 No regional lymph node metastases 
N1 Regional lymph node metastases 
  
 Distant Metastases 
M0 No distant metastases 
M1 Distant metastases 
Sobin et al.(28) 
 
It is important to note that the invasion of the prostate capsule is still classified as a T2 disease, 
as it does not spread beyond the prostate capsule.(28) 
 
Organ-confined tumours can therefore be classified postoperatively as T1c or T2. In this thesis 
our focus will be on T2 tumours, as the T1c stage classification is allocated to conditions where 
the final histological examination shows no residual tumour.  
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 A very unique characteristic of prostate cancer is that it can also be defined by the 
differentiation of the glands in the prostate cancer itself, first described by Gleason in 1966 and 
known as the Gleason Score. The score ranges from grade 1 to grade 5; grade 1 being a well-
differentiated cellular pattern and grade 5 being a poorly-differentiated cellular pattern. The 
most common and second most common Gleason grades are added together to provide us 
with the Gleason score. The lower the score, the less aggressive the cancer is. The most recent 
modification of the grading system by the International Society of Urologic Pathologists was in 
2005.(29)  
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 Table 3. 2005 International Society of Urological Pathology Modified Gleason System 
Pattern 1 
Circumscribed nodule of closely packed but separate, uniform, rounded to oval, 
medium-sized acini (larger glands than pattern 3) 
 
Pattern 2 
Like pattern 1, fairly circumscribed, yet at the edge of the tumour nodule there may be 
minimal infiltration 
Glands are more loosely arranged and not quite as uniform as Gleason pattern 1 
 
Pattern 3 
Discrete glandular units 
Typically smaller glands than seen in Gleason pattern 1 or 2 
Infiltrates in and amongst non-neoplastic prostate acini 
Marked variation in size and shape 
 
Pattern 4 
Fused microacinar glands 
Ill-defined glands with poorly formed glandular lumina 
Large cribriform glands 
Cribriform glands 
Hypernephromatoid 
 
Pattern 5 
Essentially no glandular differentiation, composed of solid sheets, cords, or single cells 
Comedocarcinoma with central necrosis surrounded by papillary, cribriform, or solid masses 
 
Epstein et al.(30) 
 
Of note however is that there is often discordance between the Gleason Score found on the 
biopsy specimen and the Gleason Score found on the final specimen after radical 
prostatectomy. In a recent study it was shown that concordance between the two pathology 
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samples only occurred 58% of the time and that the Gleason Score was higher on the final 
prostate sample in 38% of the cases.(31)  
 
A low Gleason Score (6 or less) on final histology is usually also associated with a low tumour 
stage (pT2N0 (83%), pT3N0 (14%), pT4N0 (0.1%) and pTN1 (2%)). Unfortunately this however 
does not preclude PSA recurrence (26% at 15years) and local recurrence (20% at 15years) at a 
later stage.(32) 
 
2.5 The Treatment Options in organ-confined Prostate Cancer 
 
The treatment advised for organ-confined and contained prostate cancer depends on 
numerous variables. The different options will be discussed below.  
2.5.1 Watchful Waiting 
0ther terms also used for this treatment option are “deferred treatment” or “symptom-guided 
treatment”. Increased screening worldwide, has resulted in a higher incidence of small, 
localised, well-differentiated prostate cancers, the treatment of which would be of no benefit 
to the patient.(20) It is often difficult to define which tumours can be classified into 
“insignificant or small”.(33) Despite this, the group of patients falling into this category have a 
less than 10 year life expectancy and would the prostate cancer become symptomatic, they 
would also only be treated symptomatically. The aim of this is to avoid overtreatment and a 
concomitant decrease in the quality of life, as treatment itself carries a high morbidity and is 
associated with an increased mortality.(20) In a study conducted in the USA, after a 7-year 
follow up, 41% of patients on watchful waiting remained free from any form of treatment. The 
remaining patients had either received radiotherapy or brachytherapy (34%), hormone therapy 
(16%) or even prostatectomy (10%),(34) showing that treatment could be avoided in nearly half 
of the patients.  
2.5.2 Active Surveillance 
The rationale behind this treatment option is that a very well-selected group of people with low 
risk disease will have a very low rate of progression. Abstinence from treatment will avoid the 
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unnecessary treatment of patients with a low progression rate. At the same time, close 
monitoring will also identify those patients requiring definitive treatment. The main difference 
between this approach and ‘watchful waiting’ is that in this approach, patients will have 
decisive, radical treatment if there is disease progression. Active surveillance is also often 
considered a strategy to “buy time”, as often the quality of life post-intervention, especially 
with regard to potency and continence, is poorer than that before any form of intervention. 
Some eligibility criteria have been suggested for active surveillance, namely: clinically confined 
prostate cancer, a Gleason Score of 7 or below and a PSA level of less than 15-20ng/ml. Criteria 
used to define cancer progression are:  PSA doubling time of between two and four years and a 
Gleason Score progression of more than or equal to 7. However these indicators are have not 
been properly validated and currently it is not possible to make an evidence-based 
recommendation on when to continue active surveillance and when to start treatment.(20) In 
one of the most well-designed models for a statistical analysis of factors relating to active 
surveillance, Epstein found that there was a 95% predictive value for identifying “significant” 
cancer preoperatively, but only a 66% predictive value for identifying “insignificant” cancer, 
demonstrating the difficulty of deciding which patients to assign to active surveillance.(2) This 
said, this approach is often used in patients where a diagnosis of a well-differentiated prostate 
cancer is made after a transurethral resection of the prostate (Stage T1a and T1b).(35) In taking 
this treatment option, patients need to be well informed that there is always the risk that a 
curable cancer may progress to being incurable while on the active surveillance program.(20) In 
a Finnish study, patients on active surveillance indicated that their quality of life was the same 
as those of the general population with regard to general, mental and physical health. The 
stressors of this treatment strategy did not have any influence on urinary or erectile functions, 
demonstrating that where patients are counselled fully in advance, they still have a good 
quality of life prior to the commencement of definitive treatment.(36)  
2.5.3 Radical Prostatectomy 
The surgical treatment of prostate cancer consists of removing the entire prostate gland, 
situated between the urethra and the bladder, as well as the seminal vesicles and periprostatic 
fat with the aim of achieving negative margins. Often a bilateral pelvic lymph node dissection is 
performed simultaneously. The main advantage of this procedure is that if performed skilfully, 
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it offers the possibility of cure with minimal damage to surrounding tissue. The other benefit 
being that it provides accurate pathological tumour staging as the removed specimen can be 
examined ex vivo.(2) This procedure is offered to patients with localised disease and a life 
expectancy of more than ten years, with the goal of eradication of the disease. Unfortunately it 
often entails significant morbidity with regards to continence and potency,(20) with a nerve-
sparing operation (unilaterally or bilaterally) being performed to try and prevent the adverse 
effects on potency. The operation still remains the gold standard in the treatment of organ-
confined prostate cancer. The individual surgical techniques will be discussed in Section 2.6. 
2.5.4 Radiotherapy 
External beam radiation therapy (EBRT) involves the use of gamma rays, usually photons, 
directed at the prostate. The therapy can be used on its own or in combination with hormone 
therapy.(37) Unfortunately there are no randomized control trails comparing EBRT with radical 
prostatectomy, but the general consensus is that the overall survival rate as well as the 
complication rate is comparable with that of radical surgery.(20) In a retrospective study by 
Boorijan et al high risk patients who had had a radical prostatectomy were compared to those 
who had undergone EBRT plus hormone therapy and EBRT alone. The 10-year cancer-specific 
survival rate was 92%, 92% and 88% respectively. The risk of all causes of mortality was 
however slightly higher in EBRT and hormone therapy group.(38) In the most advanced centres, 
EBRT consists of scanning the patient and transferring the 3D information on the target volume 
and safety margin into a planning system. At the time of irradiation, adaptations to the 
contours of the target volume can be done automatically. This is often a multidisciplinary 
approach between physicians, physicists, dosimeters, radiographers, radiologists, radiology 
oncologists and computer scientists. Biochemical disease-free survival is higher if the radiation 
dose is above 72Gy as compared to below 72Gy in low volume disease. Rarely will a radiation 
dose of more than 81Gy be given in the light of the danger of radiation toxicity.(20) 
2.5.5 Brachytherapy 
Brachytherapy is usually a safe and minimally invasive form of treatment that only requires only 
a short hospitalisation stay. Typically, a transperineal access, accompanied by transrectal 
ultrasound, is used to insert and implant iodine-125 or palladium-103 particles (often referred 
to as ‘seeds’) into the prostate.(2, 3) There are certain eligibility criteria that should be adhered 
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to when using this form of therapy. These are: a clinical tumour stage of T1b-T2a N0 M0; a 
Gleason Score of 6 or less on a sufficient amount of biopsies; an initial PSA of less than 10ng/ml; 
the presence of cancer in less than 50% of the biopsy cores; a prostate volume of less than 
50cm3 and an International Prostatic Symptom Score (IPSS) of less than 12. Patients with low 
risk prostate cancer are good candidates for this type of therapy. Patients who have received 
more than 140Gy by Day 90 have a significantly higher biochemical control rate after four years 
than patients receiving less than 140Gy.(20) In a recent study, the 5-year prostate specific 
antigen relapse-free survival for low, intermediate and high risk patients was 98%, 95% and 
80%, respectively.(39) 
2.5.6 Hormone Therapy 
Hormone therapy is not used as the first line therapy in locally contained prostate cancer, but 
has found its place in advanced prostate cancer, as a therapy in recurrent disease after 
definitive treatment or as part of a multimodality approach. All hormone therapy is based on 
the fact that prostate cells are dependent on androgens for growth and proliferation and 
therefore tumour growth is be hampered by depriving these cells of testosterone. There are 
three main approaches to this therapy: (1) suppression of the secretion of testicular androgens,  
(2) inhibition of the action of the circulating androgens on the prostate at the level of the 
receptors and (3) suppression of intracellular androgen synthesis. The combination of 1+2 is 
known as complete (maximal or total) androgen blockade.(2, 20) 
 
2.6 The Surgical Treatment of Prostate Cancer 
 
Young first performed the radical prostatectomy at the beginning of the 20th century, using the 
perineal approach. Memmelaar and Millin were the first to perform the retropubic 
prostatectomy. The surgical removal of the prostate is to date the only treatment that has been 
shown to benefit cancer-free survival in comparison to conservative management in 
randomised control trials.(20) The surgical treatment of prostate cancer can be divided into 
three main areas: open radical prostatectomy, of which the most common is the retropubic 
radical prostatectomy (RRP), but which also includes the perineal radical prostatectomy; the 
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laparoscopic radical prostatectomy (LRP) and the newest of the surgical techniques the robotic-
assisted (laparoscopic) radical prostatectomy (RARP).(2) 
2.6.1 Radical retropubic prostatectomy 
The Radical Retropubic Prostatectomy (RRP) is the most common performed prostatectomy, as 
urologists, due to its familiarity, often prefer it above other surgical techniques. It has a low risk 
of rectal injury and provides ready access for the pelvic lymphadenectomy. If wanted, the 
neurovascular bundles can be preserved in a procedure known as a nerve-sparing 
prostatectomy.(2) 
2.6.2 Total perineal prostatectomy 
This surgical approach is an acceptable one when experienced surgeons perform it. This surgery 
often results in less blood loss, but it does have the disadvantage that it does not provide 
access for pelvic lymph node dissection. It is also associated with a high rectal injury rate and a 
nerve-sparing procedure is often not possible.(2)  
2.6.3 Laparoscopic radical prostatectomy 
The Laparoscopic Radical Prostatectomy (LRP) is often referred to as being the most difficult 
form of prostatectomy and is only performed by surgeons experienced in the field of 
laparoscopy. This form of surgery is often accompanied by less bleeding, better visualisation, 
less postoperative pain and a shorter convalescence period. However it does require a 
transperitoneal approach (an extraperitoneal approach is also possible, although it is more 
technically challenging), which carries a greater risk for bowl injury, postoperative obstruction 
and vascular injury. It has often been criticised for having a higher risk of severe complications 
and difficulty in achieving hematostasis without thermal injury to the neurovascular bundle. 
Postoperative bleeding may also be more prominent due to the decrease in intra-abdominal 
pressure at the end of surgery.(2) 
2.6.4 Robotic-assisted radical prostatectomy  
Overall robotic surgery is fast becoming a leading form of surgery in many domains. Since 2007 
the number of robotic surgeries worldwide has nearly tripled from 80000 to 205000, with the 
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radical prostatectomy leading the way.(40) This operative technique will be discussed in depth 
in Section 2.7. 
 
2.7 Robotic-assisted radical prostatectomy 
 
Robotic-surgery, here referring to the da Vinci© System produced by Intuitive surgical© Inc. 
Sunnyvale Cal, USA, was first introduced to the open market in 1999 and first used by cardiac 
surgeons. This operating technique was introduced in Urology for the first time in 2001 when 
Binder and Kramer performed 10 radical prostatectomies in Frankfurt.(41) Initially the goal of 
using this new surgical technique was to minimise blood loss, decrease postoperative pain, 
shorten the convalescent period and improve cosmetics. It was also hoped that it would 
improve urinary incontinence and potency, the two major setbacks often associated with a 
radical prostatectomy. Contrary to laparoscopic surgery, it is claimed that robotic surgery has a 
much shorter learning curve. The technical advantages above conventional laparoscopy are the 
3D viewing and magnification, elimination of surgeon tremor, direct eye-hand coordination as 
well as instruments that facilitate fine dissection.(42) The practical advantage being that of the 
ease in which one can tie sutures and perform the vesicourethral anastomosis.(2) Despite all of 
this, superiority with regard to oncological and functional outcome has not been proven. 
Prospective trials are urgently required, although it seems that in the USA and in some areas of 
Europe, the Robotic-assisted Radical Prostatectomy (RARP) is already becoming the new gold 
standard in organ-confined prostate cancer surgery.(20) 
2.7.1 The Surgical Technique 
The original robotic surgery techniques were designed to enable trauma surgery on the 
battlefield, from a safe distance. The surgeon, who is seated at the console, uses finger-
controlled movements to manipulate the surgical instruments at a different site. Specialised 
software is used to transfer the motion of the fingers, without delay, to the microsurgical 
instruments. A variety of instruments can be used and exchanged at the 8mm port by the 
surgical assistant who, scrubbed and sterile, is at the side of the patient. The instruments used 
have special wrist joints which allow 360° movement in the confined pelvis. Another advantage 
for the surgeon is that unlike in laparoscopic surgery where counterintuitive movements must 
24 
to be learnt (moving the external part of the instrument to the right moves the internal part of 
the instrument to the left), robotic surgery, although using laparoscopic instruments, allows the 
surgeon to use the same hand movements as in open surgery. Two optic lenses are aligned side 
by side at the end of the camera which allows the surgeon three-dimensional vision. The 
possible shorter learning curve in robotic surgery is credited to these factors and also explains 
why the company that markets robotic surgery is also called “Intuitive”.(43) Criticism of the 
technique often focuses on the fact that unlike open surgery there is no tactile stimulation and 
the surgeon has to rely on visual cues only.(42) In a study designed by Tewari et al. to try and 
disprove this fact, visual cues were used to train robotic surgeons, with the end goal being the 
avoidance of posterolateral positive surgical margins. By following cues such as the observation 
of the periprostatic fascia compartment, colour and texture of tissue, periprostatic veins, signs 
of inflammation and visualisation of a freely, separating bloodless plane showing areolar tissue, 
the overall posterolateral positive surgical margin rate was 2,1%. This is extremely low.(44) 
 
Unlike RRP, the surgical approach is usually transperitoneal. This is associated with a greater 
incidence of bowel injury and postoperative ileus. Haematoma and urinary leakage may also be 
managed easier in an extraperitoneal approach and although an extraperitoneal approach has 
been performed successfully used in robotic surgery, it is not the approach most commonly 
used. Some surgeons would view previous intra-abdominal surgery as a relative 
contraindication to RARP. An additional person using an extra port with laparoscopic 
instrumentation provides surgical assistance.(42)  
2.7.2 The Outcome 
Often, especially when comparing surgical techniques, the oncological control, continence and 
potency are discussed. In most cases the jury is still out on which radical surgical technique 
provides the best outcomes and many contradictory reports can be found in the literature.  
 
In a population-based observational cohort study conducted in the USA in 2009, it was found 
that the amount of men undergoing minimally invasive radical prostatectomy (MIRP) in 
comparison to RRP increased from 9,2% in 2003 to 43,2% in 2007. Although the complication 
rates were lower in the MIRP group, the incontinence and erectile dysfunction rates were 
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higher. The oncological outcomes were the same.(45) In a study conducted by Magheli et al. 
522 patients that had undergone RARP were matched to the same number of men that had 
undergone LRP and RRP. The positive surgical margin rate was 19,5%, 13,0% and 14,4% 
respectively, showing a statistically significant increase in positive surgical margins in patients 
undergoing a RARP. Attention should be drawn to the fact that this was the first experience of 
RARP at that centre and that the rate of biochemical recurrence for all three surgical groups 
was the same.(46) The international literature is scattered with contradictory reports and 
findings but when looking at a systematic review, performed by Ficarra et al., the evidence 
showed that LRP and RARP were more time consuming than RRP, but that all three operative 
techniques showed similar continence and potency rates, although a single prospective, non-
randomised trail did suggest better outcomes in the RARP group. The positive surgical margin 
rates were comparable.(47) Ideally prospective randomized trials comparing the RARP to other 
surgical techniques should be conducted. However, since the RARP has in many centres already 
become the gold standard in radical prostatectomy surgery, it is unlikely that such a trial will be 
forthcoming.(48) 
2.7.3 The Cost and Training Issue 
Additional issues surrounding the topic of RARP include that of training and cost. The real 
learning curve for the RARP has not yet been fully established, although there is a general 
consensus that it is shorter than that required for the LRP. A question that has arisen during the 
introduction of this technique is when a RARP program should be initiated at a centre. Some 
believe that the skills learnt performing LRP and RRP procedures can be transferred to the 
RARP, while others believe that training courses should be attended and some even believe 
that fellowships in robotic training should be implemented. A major drawback in any training 
program is that only a single surgeon only can work at a normal console at any given point in 
time.(42) 
 
Another considerable disadvantage of RARP are the costs involved. The initial cost of a da 
Vinci© System approaches $1,400 000, not to mention the annual technical support fees and 
the intraoperative expenses. The instruments also need to be exchanged after every 10 
operations. This operation can therefore only be cost-effective in high volume centres.(43) The 
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most cost-effective surgery still remains the RRP.(42) There is some debate about the total cost 
per patient, as patients undergoing a RARP are often known to have a shorter hospital stay. The 
costs for patients undergoing a RARP or a RRP from the day of admission till one year 
postoperatively were calculated in a study conducted in the USA. The cost difference per 
patient was $1200, with the RARP being the more expensive operation.(49) 
 
2.8  The Relevance of Positive Surgical Margins 
 
The goal of any curative cancer surgery is to achieve local control and therefore better the 
oncological outcome of the patient. The definition of a positive surgical margin is tumour 
present at the edge of an inked pathology specimen. A positive surgical margin is created when 
an incision is made into an extraprostatic tumour (extraprostatic disease) or when a surgeon 
accidently makes an incision into a prostate with organ-confined disease (pT2).(50) 
 
The objective of a radical prostatectomy is to completely remove the prostate cancer and 
therefore an important way to control locally confined cancer is clear surgical margins. 
Grossfeld et al described poor prognostic features with regard to cancer control as non–organ-
confined disease and extracapsular tumour; perineural, lymphovascular and seminal vesicle 
invasion, positive surgical margins and lymph node metastases.(2) The importance and the 
relevance of the positive surgical margin is that it is the only poor prognostic feature of a poor 
outcome that can be influenced by surgical technique. 
 
Positive surgical margins influence the prognosis of patients treated surgically for organ-
confined prostate cancer. In a study performed by Kin et al., where the outcome of patients 
treated with radical prostatectomy (RRP and LRP) was analysed, a statistically significant 
correlation could be seen between a positive surgical margin and biochemical recurrence 
(p=0.035). This study did however not take pathological tumour staging into account.(51) A 
closer look at research evaluating whether positive surgical margins are an independent 
prognostic marker after radical prostatectomy, research done in Norway proves that in general 
patients with positive surgical margins, irrespective of their location or extent, are at higher risk 
of PSA recurrence at a mean follow-up time of 62 months. It is noteworthy that the hazard ratio 
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is statistically significantly higher in patients with localised (pT2) disease, in comparison to 
locally advanced disease (pT3/pT4). This research emphasises the importance of clear surgical 
margins in organ-confined disease.(52) Swindle et al. examined 1389 patients who had 
undergone a RP and found the positive surgical margin rate of pT2 tumours to be 6,8% and 23% 
for pT3/pT4 tumours. Overall patients with positive surgical margins had a 10-year progression 
free probability of 58%, whereas those patients with clear margins surgical margins had an 81% 
10-year progression free probability.(50) In an article by Lake et al. the positive surgical margin 
rate in 1997 pT2 tumours that had been resected by means of a RP was supplied as 14%, of 
which 11,5% had focal positive surgical margins (<3mm) and 2,6% had extended positive 
surgical margins (>3mm). The 10-year disease free survival for patients with clear surgical 
margins, focal positive surgical margins and extended positive surgical margins, was 90%, 76% 
and 53% respectively.(53) 
 
Based on the above information, it can therefore be said that positive surgical margins, even in 
organ-confined disease leads to an increased risk in biochemical recurrence and a decreased in 
disease free survival.  
 
With this in mind, when looking at the literature present, many publications try to identify risk 
factors with regard to positive surgical margins and the radical prostatectomy. Relationships 
that have been examined in the past have been the nerve-sparing operation,(54, 55, 56) the 
learning curve (57, 58) and the prostate weight (59, 60) to mention but a few.  
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3. Goal Setting 
 
Prostate cancer is still a very actual and growing topic, especially considering the rising 
incidence due to better screening options and an increasingly aging population. Robotic-
assisted radical prostatectomy is increasingly being used to treat organ-confined prostate 
cancer and has become the gold standard of treatment at some centres. As with all 
tumour surgery the primary objective is still to provide a good oncological outcome. 
Positive surgical margins are a real risk in organ-confined cancer, and influence the overall 
disease-free survival rate. The goal of this thesis is to identify factors that can influence 
the positive surgical margin rate in organ-confined prostate cancer in the hope that by 
addressing these factors the occurrence of positive surgical margins can be curtailed and 
better oncological outcomes achieved.  
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4. Material and Methods 
4.1 Patient Selection Criteria 
 
The first robotic assisted radical prostatectomy (RARP) was performed at the University 
Clinic of Saarland on the 18th March 2006. As a recognized prostate cancer centre and due 
to the specialisation of the clinic in the operative treatment of prostate cancer, by the 
26th January 2011, 1200 patients had successfully been treated with this surgical 
technique. All patients, irrespective of outcome, who were treated by means of the RARP 
during this time period were included in this study. All operations were performed by one 
of three surgeons. Not one of the surgeons had had prior robotic surgery experience.  
 
All patients, irrespective of outcome, operated in this time span, were included in this 
study. All operations were performed by one of three surgeons. None of the surgeons had 
prior robotic surgery experience.  
 
All patients operated in this time span had been diagnosed with prostate cancer on 
prostate biopsies. These biopsies were predominantly performed in external clinics or 
private practices. Only a minority of patients had had their prostates biopsied at the 
University Clinic of Saarland itself. Most of the biopsies had been deemed necessary after 
a suspicious clinical examination, a raised PSA value or an increased PSA doubling time. 
The patients operated upon during this time period had presented with clinical stages of 
T1, T2 or T3 and none of them had had any known metastases at the time of surgery. The 
intention of the surgery was always curative and other therapeutic options such as active 
surveillance, ‘watchful waiting’, as well as radiotherapy, had been discussed with the 
patients. As the University Clinic of Saarland specialises in robotic surgery, unless there 
was a medical contraindication, all patients undergoing a radical prostatectomy were to 
be treated by means of the RARP procedure. The patients were fully informed of this fact 
prior to surgery.  
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4.2 Data Retrieval 
 
In furtherance of internal quality assessment and audit, all data from patients operated 
upon using this technique was collected retrospectively till April 2010 and from then 
onwards prospectively. The initial aim of this data-capturing strategy was to evaluate the 
surgical outcome and to this end data was collected and formatted in an excel spread 
sheet. As time progressed, additional criteria were identified and added to the excel 
spread sheet.  As such the size of the excel spread sheet grew over time.  
 
Currently, 83 different data sets are captured describing the preoperative, the 
intraoperative and the postoperative events and facts. These different data sets are 
manually entered into the excel spread sheet. The details of the patients undergoing a 
RARP could be retrieved from the theatre operating lists. Once a patient had undergone a 
RARP, irrespective of outcome, he would be added to the spread sheet. Most of the data 
that is needed can be retrieved electronically via the computer software, SAP, which is 
used throughout the clinic. However, not all data, particularly the preoperative data can 
be retrieved from the computer system. It is therefore essential that the data collection 
process be started upon admission of the patient to the hospital. If does not take place, 
valuable data could be lost.  
 
4.3 “da Vinci Worksheet” and Data Acquisition  
 
In order to facilitate the data collection process and to assure that no data is lost the “da 
Vinci Worksheet” was implemented in April 2010 (refer to Attachment no. 1). The 
admitting doctor records all pre-operative data on the first two pages of the worksheet 
on the day of the admission. On the day of discharge the discharging doctor completes 
the intra-operative as well as the postoperative information. In this manner the person 
collecting the patient data did not have to personally interview each of the patients. The 
admitting doctor regularly filled in most preoperative data, but often there were gaps in 
the data filled in by the discharging doctor as some discharges also took place over the 
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weekend. Luckily most operative and postoperative data could be retrieved via the 
discharge letters and operating reports. Data that could not be captured from these 
reports could be retrieved from the hard copy of the patient’s file. This is especially 
important with regard to the preoperative prostate biopsies, which are performed in 
clinics outside the University clinic, since these are not recorded electronically on our 
computer software.   
 
In 2011 the University Clinic of Saarland implemented the electronic capture off all 
patients’ ward files. All patients admitted after February 2009 would have their paper 
files electronically scanned into the computer system. This would enable missing data to 
be retrieved electronically if a patient was admitted after February 2009. In some patient 
cases not all data could be retrieved in this manner. An attempt to retrieve the 
outstanding data was made by writing letters to the referring urologist. However, this 
process was not always successful.   
 
Furthermore random audits of patients’ data were also performed. This demonstrated 
that at certain times, before the establishment of the “da Vinci worksheet”, the data 
captured was of poorer quality, especially regarding the preoperative data. As of 
November 2010, the data recorded before April 2010 was audited and updated using the 
above mentioned processes. 
 
4.4 Excel Spread sheet Lay out 
 
The spread sheet containing the patients information consists of 83 columns and 83 
different sets of data. Not all recorded data was included in the current study. The reason 
for documenting all necessary data is to facilitate future audits and studies. The research 
described in this paper only used information of 11 data sets, namely the following:  
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Table 4. Preoperative Data Sets 
Preoperative Data 
Preoperative PSA (ng/ml) 
Number of biopsies taking preoperatively 
Number of left-sided positive biopsies  
Number of right-sided positive biopsies  
Nerve-sparing procedure: 1=no, 2= yes 
Nerve-sparing location: 1 = right, 2 = left, 3 = bilateral 
Biopsy Quality: 0 = inadequate, 1 = adequate* 
 
Table 5. Postoperative Data Sets  
Postoperative Data 
Prostate weight (g) 
Tumour stage: pT  
Positive surgical margins: 1 = R0, 2 = R1, 3 = R2 
Positive surgical margin location: 1 = basal, 2 = lateral, 3 = apical, 4 = seminal vesicles, 
5 = multiple 
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Table 6. Definitions of the variables 
Preoperative PSA (ng/ml): The PSA value at diagnosis, also before any form of 
hormone treatment 
Number of biopsies taken preoperatively: The number of the prostate biopsies taken 
at diagnosis (Range 2 till 27) 
Number of left-sided/right-sided positive biopsies: The number of positive biopsies 
from each prostate lobe  
Nerve-sparing: The dissection and sparing of the neurovascular bundle lateral to the 
prostate (bilaterally, right or left) 
Prostate weight: The prostate weight after surgical removal, as documented by the 
examining pathologist. The prostate is weighed with the seminal vesicles.  
Tumour stage: According to the TNM 6th (2007) and TNM 7th (2010) classification  
Positive surgical margins: Microscopically proven extension of the tumour into the 
surgical dissection or cauterization margin 
Positive surgical margin location: As described by the pathologist, the area of the 
prostate where the extension of the tumour into the surgical margins was found. 
‘Multiple’ refers to several separate areas where the tumour can be found in the 
surgical margin and not a continuous positive surgical margin. 
 
*“Biopsy Quality” is a criterion that was designed in line with this study to quantify the 
quality of the preoperative biopsy, as the results of the biopsy are the basis for the 
decision to perform a radical prostatectomy or not. The results of the preoperative biopsy 
also influence the decision on whether to perform a nerve-sparing operation or not. The 
quality of the biopsy is very difficult to assess, especially since there is very limited 
information available about the different biopsy techniques used. As mentioned 
previously, most biopsies are performed at external clinics. Two criteria are used to 
evaluate whether a biopsy was of “adequate” or “inadequate” quality.   
No. 1: At least 8 biopsy cores should be removed from the prostate (in line with 
EAU Guidelines)  
No. 2: It should be possible to locate the biopsy core containing the prostate 
cancer (for example, left apex) 
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If both criteria were fulfilled the quality of the biopsy was deemed “adequate” and if 
none or only one criterion was fulfilled the biopsy was labelled as “inadequate”.  
4.5 Statistical Evaluation of Data  
 
The data collected for this study was used to create an excel pivot table where numerous 
varying parameters were compared to one another in a preliminary statistical evaluation. 
The data was also presented in tables and graphs for a better visualisation of the 
evaluation process. 
 
Once the preliminary statistical evaluation had been completed the Institute for Medical 
Biometry, Epidemiology and Medical Informatics at the University Clinic of Saarland was 
approached to perform a formal analysis. The statistical analysis was completed with the 
SPSS Software for Windows. Univariate analyses were conducted, where the association 
of one explanatory variable with one outcome variable was examined. Pearson’s 
correlation test was used to assess the linear association between two continuous 
variables. The correlation ranged from -1 to +1, with numbers close to 0 not showing a 
strong correlation. Negative numbers indicated that as the one variable increased, the 
other variable decreased, whereas positive numbers indicated that as the one variable 
increased, so did the other variable.  The Fisher exact test was also used to compare the 
outcome of two separate variables/groups as this test compares proportions between 
two or more groups. Outcomes were classified as statistically significant where the p 
value was below 0.05, as in such instances the null hypothesis had been disproven and 
the statistical variation could not be attributed to random chance.(61) 
 
Since the purpose was to identify variables that would predict positive surgical margins, 
only variables that were statistically significant were used in the multivariable analysis. 
The goal of the multivariable analysis was to examine the association of multiple variables 
with the outcome variable so that independent risk factors for positive surgical margins 
could be identified. The logistic regression analysis included a 95% confidence interval as 
well as a corresponding p value.(61) 
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5. Results 
5.1 Tumour Staging  
 
Elsewhere in this thesis, it is explained that prostate cancer is staged according to the TNM 
classification. Only the pathological, not the clinical stage, was examined in this study. A pT2 
tumour stage represents cancers that are still organ-confined and have not yet advanced 
extracapsularly. As previously clarified the pT1c tumour stage will not be included in our 
analyses as no tumour is found on the final histology specimen.  
 
Therefore the first objective of this study was to further classify the patients with a pT2 tumour 
stage amongst the 1200 patients who had been selected for this study. The pT2 tumour stage 
was further divided into its subcategories, namely pT2a, pT2b and pT2c. 
 
 Table 7. Tumour Stage Division  
Tumour stage (pT) Number of patients (n = 1200) Percentage (%) 
1c 6 0.5% 
2a 91 7.6% 
2b 5 0.4% 
2c 761 63.4% 
3a 213 17.8% 
3b 119 9.9% 
4 5 0.4% 
 
 
 
 
 
 
 
Figure 4. Tumour Stage distribution 
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This subdivision demonstrates that pT2 tumours are the most common tumour found in the 
study population, with the majority of pT2 tumours falling within the pT2c group.  
 
5.2 Positive surgical margins 
 
The positive surgical margin rate in patients with a pT2 tumour stage was calculated. In this 
analysis pT2a and pT2b were grouped together and pT2c was evaluated separately. The positive 
surgical margin rate for the pT2a and pT2b tumour stage as compared to the pT2c tumour stage 
was 4.2% and 8.4% respectively, with the total positive surgical margin rate being 7.9%, where 
R0 = negative surgical margins and R1 = positive surgical margins.  
 
Table 8. Surgical margins for pT2 tumour stage 
Tumour stage R0 R1 Number of Patients (n = 857) Percentage R1 (%) 
2a + 2b 92 4 96 4.2% 
2c 697 64 761 8.4% 
 
Pearson’s Correlation Test 2.101 
Fisher Exact Test 0.226 
 
This calculation demonstrates that there is no statistically significant difference in the positive 
surgical margin rate between the tumour stage pT2 (a and b) and pT2c. 
 
5.3 Positive surgical margins with regard to a nerve-sparing operation  
 
The effect of a nerve-sparing operation on the positive surgical margin rate was to be 
evaluated. Of the 857 patients, 546 (63.7%) had had a nerve-sparing operation. This included a 
bilateral as well as unilateral nerve-sparing operation. When a nerve-sparing procedure was 
used the positive surgical margin rate was 10.3% (56/546) whereas when no nerve-sparing 
procedure was used the positive surgical margin rate was only 3.9% (12/311).  
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Table 9. Positive Surgical Margins with a Nerve-sparing Operation 
 
Positive Surgical Margin  
R0 R1 Total 
Stage pT2 Non Nerve-sparing Amount 299 12 311 
  Percentage 96.1% 3.9% 100% 
 Nerve-sparing Amount 490 56 546 
  Percentage 89.7% 10.3% 100% 
Total   789 68 857 
   92.1% 7.9% 100% 
 
Pearson’s Correlation Test 11.476 
Fisher Exact Test 0.001 
 
The above-mentioned values demonstrate that there is a statistically significant increase in the 
positive surgical margin rate when a nerve-sparing operation is performed.  
 
5.4 The Bilateral and Unilateral Nerve-sparing Operation 
5.4.1 The relationship between a Positive Surgical Margin Rate and a Unilateral or 
Bilateral Nerve-sparing Operation  
Prior to performing a nerve-sparing operation, the surgeon must choose between a bilateral or 
unilateral (right or left-sided) nerve-sparing procedure. The majority of patients in this study 
underwent a bilateral nerve-sparing procedure, 62.5% (341/546). The positive surgical margin 
rate for a bilateral nerve-sparing procedure is 12.3% (42/341). The remaining patients who had 
the unilateral nerve-sparing operation, were left with a positive surgical margin rate of 6.8% 
(14/205).  
 
38 
Table 10. The Positive Surgical Margin Rate and a Unilateral and Bilateral Nerve-sparing 
Operation 
 
Positive Surgical Margin  
R0 R1 Total 
Stage pT2 Bilateral Nerve-sparing Amount 299 42 341 
  Percentage 87.7% 12.3% 100% 
 Unilateral Nerve-sparing Amount 191 14 205 
  Percentage 93.2% 6.8% 100% 
Total   490 56 546 
   89.7% 10.3% 100% 
 
Pearson’s Correlation Test 4.259 
Fisher Exact Test 0.042 
 
The above calculation demonstrates that there is a statistically significant increase in the 
positive surgical margin rate where a bilateral nerve-sparing operation is performed in 
comparison to a unilateral nerve-sparing operation. 
 
5.4.2 The Relationship between a Positive Surgical Margin rate and a left-sided versus a 
right-sided Nerve-sparing Operation  
 
Table 11. Left-sided versus Right-sided Nerve-sparing Operation 
 
Positive Surgical Margin  
R0 R1 Total 
Stage pT2 Left-sided Nerve-sparing Amount 116 12 128 
  Percentage 90.6% 9.4% 100% 
 Right-sided Nerve-sparing Amount 75 2 77 
  Percentage 97.4% 2.6% 100% 
Total   191 14 205 
   93.2% 6.8% 100% 
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Pearsons Correlation Test 3.422 
Fischer Exact Test 0.086 
 
No statistically significant difference was found between positive surgical margin rate and a 
left-sided or right-sided nerve-sparing procedure. 
 
5.5 Prostate weight 
5.5.1 Prostate Weight Distribution  
All specimens sent for pathological evaluation postoperatively were weighed. The prostate and 
the seminal vesicles were weighed as one unit. Six prostate weight categories were established 
in order to facilitate all further calculations. 
 
Table 12. Prostate Weight Categories  
Prostate weight category Weight Number of patients 
Category 1 ≤35g 114 
Category 2 35.1-45g 158 
Category 3 45.1-55g 213 
Category 4 55.1-65g 145 
Category 5 65.1-75g 92 
Category 6 >75g 135 
 
The mean prostate weight was 52g and the average prostate weight was 55.8g, ranging from 3g 
to 158g. 
 
 
 
 
 
 
 
Figure 5. Prostate weight distribution 
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5.5.2 The relationship between a Positive Surgical Margin Rate and Prostate Weight 
In order to ascertain whether the prostate weight had any bearing on the positive surgical 
margin rate, the positive surgical margin rate was calculated for each weight category. Marked 
differences were found in the positive surgical margin rate depending on the prostate weight.  
 
Table 13. Positive Surgical Margins and the Prostate Weight 
 
Positive Surgical Margin  
R0 R1 Total 
Stage pT2 Weight Category 1 Amount 97 17 114 
 ≤35g Percentage 85.1% 14.9% 100% 
 Weight Category 2 Amount 146 12 158 
 35.1-45g Percentage 92.4% 7.6% 100% 
 Weight Category 3 Amount 197 16 213 
 45.1-55g Percentage 92.5% 7.5% 100% 
 Weight Category 4 Amount 140 5 145 
 55.1-65g Percentage 96.6% 3.4% 100% 
 Weight Category 5 Amount 84 8 92 
 65.1-75g Percentage 91.3% 8.7% 100% 
 Weight Category 6 Amount 125 10 135 
 >75g Percentage 92.6% 7.4% 100% 
Total   789 68 857 
   92.1% 7.9% 100% 
  
Pearson’s Correlation Test 11.795 
Fisher Exact Test 0.045 
 
This calculation demonstrates that the positive surgical margin rate has a statistically significant 
correlation to the prostate weight (p=0.045). It is noteworthy that the first weight category 
(under 35g) has the numerically highest positive surgical margin rate. This finding was followed-
up by further calculations comparing the patients in category 1 (prostatic weight of under 35g) 
to those in the rest of the study population. 
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5.5.3 The Influence of a Low Prostate Weight on the Positive Surgical Margin Rate 
As previously demonstrated, the prostate weight does have an impact on the positive surgical 
margin rate. Of note is the very high positive surgical margin rate in patients with a low 
prostate weight. For this reason two separate categories for weight were created, namely those 
patients with a prostate weight equal to or less than 35g and those with a prostate weight of 
more than 35g.  
 
Table 14. Positive Surgical Margins and a low Prostate Weight 
 
Positive Surgical Margin  
R0 R1 Total 
Stage pT2 Weight Category 1 Amount 97 17 114 
 ≤35g Percentage 85.1% 14.9% 100% 
 Weight Category 2 Amount 692 51 743 
 >35g Percentage 93.1% 6.9% 100% 
Total   789 68 857 
   92.1% 7.9% 100% 
 
Pearson’s Correlation Test 8.764 
Fisher Exact Test 0.008 
 
The above calculation demonstrates a statistically clear correlation between a low prostate 
weight of under 35g and positive surgical margins. 
 
5.5.4 The Relationship between Positive Surgical Margins, Prostate Weight and a Nerve-
sparing Operation 
Once the correlation between a nerve-sparing operation and the positive surgical margin rate 
was observed, the question arose as to whether this would also be true of the prostate weight 
and whether one specific weight category was at particular risk when a nerve-sparing operation 
was performed. The patients were first divided into groups of those who had not undergone a 
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nerve-sparing operation and those who had. Once again the positive surgical margin rate per 
weight category was calculated.  
 
Table 15. The Positive Surgical Margins relating to Prostate Weight and a non Nerve-sparing 
Operation 
Non nerve-sparing operation 
Positive Surgical Margin  
R0 R1 Total 
Stage pT2 Weight Category 1 Amount 30 1 31 
 ≤35g Percentage 96.8% 3.2% 100% 
 Weight Category 2 Amount 37 0 37 
 35.1-45g Percentage 100% 0% 100% 
 Weight Category 3 Amount 70 2 72 
 45.1-55g Percentage 97.2% 2.8% 100% 
 Weight Category 4 Amount 56 1 57 
 55.1-65g Percentage 98.2% 1.8% 100% 
 Weight Category 5 Amount 40 4 44 
 65.1-75g Percentage 90.9% 9.1% 100% 
 Weight Category 6 Amount 66 4 70 
 >75g Percentage 94.4% 5.7% 100% 
Total   299 12 311 
   96.1% 3.9% 100% 
 
Pearson’s Correlation Test 6.323 
Fisher Exact Test 0.236 
 
When a non nerve-sparing operation was performed no significant relationship between the 
prostate weight and the positive surgical margin rate could be demonstrated.  
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Table 16. The Positive Surgical Margins relating to Prostate Weight and a Nerve-sparing 
Operation 
Nerve-sparing operation 
Positive Surgical Margin  
R0 R1 Total 
Stage pT2 Weight Category 1 Amount 67 16 83 
 ≤35g Percentage 80.7% 19.3% 100% 
 Weight Category 2 Amount 109 12 121 
 35.1-45g Percentage 90.1% 9.9% 100% 
 Weight Category 3 Amount 127 14 141 
 45.1-55g Percentage 90.1% 9.9% 100% 
 Weight Category 4 Amount 84 4 88 
 55.1-65g Percentage 95.5% 4.5% 100% 
 Weight Category 5 Amount 44 4 48 
 65.1-75g Percentage 91.7% 8.3% 100% 
 Weight Category 6 Amount 59 6 65 
 >75g Percentage 90.8% 9.2% 100% 
Total   490 56 546 
   89.7% 10.3% 100% 
 
Pearson’s Correlation Test 10.755 
Fisher Exact Test 0.056 
 
As with the non nerve-sparing operation the prostate weight does not seem to be statistically 
significant when evaluating the above-mentioned six categories in patients who have 
undergone a nerve-sparing operation.  
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Figure 6. Positive surgical margin distribution according to prostate weight and the nerve-
sparing operation 
5.5.5 The Influence of a Low Prostate Weight and a Nerve-sparing Operation on the 
Positive Surgical Margin Rate.  
Since the positive surgical margin rate in the prostate weight category of equal to or less than 
35g was found to be statistically significant, a decision was made to compare this weight 
category to the above 35g weight category, taking the nerve-sparing and non nerve-sparing 
operation into consideration.  
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Table 17. The Positive Surgical Margins relating to a low Prostate Weight and a non Nerve-
sparing Operation 
Non Nerve-sparing 
Positive Surgical Margin  
R0 R1 Total 
Stage pT2 Weight Category 1 Amount 30 1 31 
 ≤35g Percentage 96.8% 3.2% 100% 
 Weight Category 2 Amount 269 11 280 
 >35g Percentage 96.1% 3.9% 100% 
Total   299 12 311 
   96.2% 3.8% 100% 
 
Pearson’s Correlation Test 0.033 
Fisher Exact Test 1.000 
 
When a non nerve-sparing procedure is performed no correlation can be found between the 
positive surgical margin and the prostate weight can be found.   
 
Table 18. The Positive Surgical Margins relating to a low Prostate Weight and a Nerve-sparing 
Operation 
Nerve-sparing 
Positive Surgical Margin  
R0 R1 Total 
Stage pT2 Weight Category 1 Amount 67 16 83 
 ≤35g Percentage 80.7% 19.3% 100% 
 Weight Category 2 Amount 423 40 463 
 >35g Percentage 91.4% 8.6% 100% 
Total   490 56 546 
   89.7% 10.3% 100% 
 
Pearson’s Correlation Test 8.512 
Fisher Exact Test 0.009 
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A statistically significant increase in the positive surgical margin rate is found when a nerve-
sparing operation is performed in a patient with a low prostate weight of equal to or less than 
35g. 
 
 
Figure 7. Positive surgical margin distribution in a low prostate weight group 
 
5.5.6 The Relative Risk  
The relative risk for patients with a low prostate weight of having positive surgical margins after 
their surgical procedures when compared to patients with a higher prostatic weight, is 
calculated as:  
Formula 
   Percentage PSM if ≤35g/Percentage PSM if >35g 
   14.9/6.9 
   = 2.1 
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The relative risk in having positive surgical margins, for the patient with a prostate weight of 
equal to or less than 35g, in comparison to a patient with a prostate weight of above 35g, is 2.1 
fold. 
 
5.6 Localisation of positive surgical margins 
 
This study also identified the anatomical area(s) of the prostate where the most positive 
surgical margins were found.  These areas were identified by the pathologist on the specimen 
itself. Four specific areas of the prostate were identified, namely: the apex, the base, the lateral 
areas and the seminal vesicles. If several positive margins were seen on the specimen, the 
positive surgical margin area was classified as ‘multiple’. 
5.6.1 Distribution of the localisation of the positive surgical margins 
 
Table 19. Localisation of Positive Surgical Margins 
Localisation of positive surgical margin Number Percentage 
Apex 40 58.8% 
Base 19 27.9% 
Lateral 5 7.4% 
Seminal Vesicles 1 1.5% 
Multiple 3 4.4% 
Total 68 100% 
 
Only a very small number of patients had positive surgical margins within the lateral, seminal 
vesicular and multiple areas. For statistical purposes, it was therefore decided that all further 
calculations involving these parameters would be divided into three groups, namely: apex, base 
and ‘other’, where the third category or group would encompasses all the remaining 
localisations.  
 
 
 
48 
 
 
 
 
 
 
 
 
 
 
Figure 8. Distribution of positive surgical margins 
5.6.2 The Relationship between a Nerve-sparing Operation and the Localisation of the 
Positive Surgical Margin 
An attempt was made to identify whether a nerve-sparing operation would have any bearing 
on the localisation of the positive surgical margins. Once again the patients were divided into 
separate groups depending on whether a nerve-sparing operation was performed or not, with 
the following results: 
 
Table 20. The Nerve-sparing Operation and the Localisation of the Positive Surgical Margin 
 
Localisation  
Apex Base Other Total 
Nerve-sparing Without Amount 10 1 1 12 
  Percentage 83.3% 8.3% 8.3% 100% 
 With Amount 30 18 8 56 
  Percentage 53.6% 32.1% 14.3% 100% 
Total  Amount 40 19 9 68 
  Percentage 58.8% 27.9% 13.2% 100% 
 
Pearson’s Correlation Test 3.758 
Fisher Exact Test 0.153 
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These calculations were not statistically significant and a relationship between the localisation 
of the positive surgical margin and a nerve-sparing operation could not be determined. 
 
5.7 The Learning Curve and pT2 Tumours 
5.7.1 Number of pT2 Patients operated 
In order to establish whether a positive trend could be seen in relation to the positive surgical 
margin rate over time, the 1200 patients were divided into three groups of 400 patients each. 
Each subsequent group showed a steady decline in the number of pT2 patients, as over time 
more patients with advanced pathological stages received operations.  
 
Table 21. Number of pT2 Patients operated over Time 
Patient Number Number of patients with pT2 Tumours Percentage 
1-400 306 76.5% 
401-800 297 74.3% 
801-1200 254 63.5% 
Total 857 71.4% 
 
5.7.2 The Amount of Nerve-sparing Operations over Time. 
Not only had the number of pT2 tumours decreased over time. There was also a steady decline 
in the number of patients who had undergone a nerve-sparing operation.  
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Table 22. Nerve-sparing Operations over Time 
 
Nerve-sparing  
Without With Total 
Patient Nr 1-400 Amount 74 232 306 
  Percentage 24.2% 75.8% 100% 
 401-800 Amount 112 185 297 
  Percentage 37.7% 62.3% 100% 
 801-1200 Amount 125 129 254 
  Percentage 49.2% 50.8% 100% 
Total   311 546 857 
   36.3% 63.7% 100% 
 
Pearson’s Correlation Test 38.005 
Fisher Exact Test <0.0001 
 
These calculations demonstrate that there is a statistically significant decrease over time in the 
number of patients who have received a nerve-sparing operation. 
5.7.3 The Amount of Bilateral Nerve-sparing Operations performed 
Furthermore, since as previously demonstrated, there was a difference in the positive surgical 
margin rate depending on whether a bilateral or unilateral nerve-sparing operation had been 
performed, the amount of bilateral versus unilateral nerve-sparing operations was also 
calculated over time.  
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Table 23. The Amount of Bilateral Nerve-sparing Operation over Time 
 
Nerve-sparing  
Unilateral Bilateral Total 
Patient Nr 1-400 Amount 92 140 232 
  Percentage 39.7% 60.3% 100% 
 401-800 Amount 68 117 185 
  Percentage 36.8% 63.2% 100% 
 801-1200 Amount 45 84 129 
  Percentage 34.9% 65.1% 100% 
Total   205 341 546 
   37.5% 62.5% 100% 
 
Pearson’s Correlation Test 0.879 
Fisher Exact Test 0.644 
 
Although there was a decrease in the percentage rate of patents who had undergone a nerve-
sparing operation, there was a steady increase in the percentage rate of patients who had had 
a bilateral nerve-sparing operation over time. This was, however, not statistically significant.  
 
5.7.4 The Positive Surgical Margin Rate over Time 
The global positive surgical margin rate over time was calculated in order to ascertain whether 
there had been a positive learning curve as demonstrated by a decrease in the positive surgical 
margin rate. The positive surgical margin rate of the pT2 tumours per 400 patients operated 
upon was once again calculated, with the following results:  
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Table 24. Positive Surgical Margin rate over Time 
 
Positive surgical margin  
Negative Positive Total 
Patient Nr 1-400 Amount 269 37 306 
  Percentage 87.9% 12.1% 100% 
 401-800 Amount 279 18 297 
  Percentage 93.9% 6.1% 100% 
 801-1200 Amount 241 13 254 
  Percentage 94.9% 5.1% 100% 
Total   789 68 857 
   92.1% 7.9% 100% 
 
 
Pearson’s Correlation Test 11.424 
Fisher Exact Test 0.003 
 
A statistically significant decrease in the number of pT2 patients with positive surgical margins 
over time could be demonstrated.  
 
5.7.5 The Relation between a Nerve-sparing Operation and the Positive Surgical Margin 
Rate over Time 
Having proven the decrease in the overall positive surgical margin rate, the impact of the nerve-
sparing as well as the non-nerve-sparing operations on the positive learning curve was 
evaluated.  
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Table 25. The Positive Surgical Margin Rate in Relationship to the non Nerve-sparing Operation 
over Time 
Non-nerve-sparing operation 
Positive surgical margin  
Negative Positive Total 
Patient Nr 1-400 Amount 71 3 74 
  Percentage 95.9% 4.1% 100% 
 401-800 Amount 109 3 112 
  Percentage 97.3% 2.7% 100% 
 801-1200 Amount 119 6 125 
  Percentage 95.2% 4.8% 100% 
Total   299 12 311 
   96.1% 3.9% 100% 
 
Pearson’s Correlation Test 0.727 
Fisher Exact Test 0.695 
There was no decrease in the positive surgical margin rate in patients who had undergone a 
non-nerve-sparing operation.  
 
Table 26. The Positive Surgical Margin Rate in Relationship to the Nerve-sparing Operation over 
Time 
Nerve-sparing operation 
Positive surgical margin  
Negative Positive Total 
Patient Nr 1-400 Amount 198 34 232 
  Percentage 85.3% 14.7% 100% 
 401-800 Amount 170 15 185 
  Percentage 91.9% 8.9% 100% 
 801-1200 Amount 122 7 129 
  Percentage 94.6% 5.4% 100% 
Total   490 56 546 
   89.7% 10.3% 100% 
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Pearson’s Correlation Test 9.074 
Fisher Exact Test 0.011 
 
Patients that had undergone a nerve-sparing operation showed a steady decline in positive 
surgical margins over time. This calculation proved a statistically significant positive learning 
curve.  
 
 
Figure 9. Positive surgical margin rate over time, depending on the nerve-sparing operation 
 
5.8 The Quality of the Preoperative Biopsy 
 
As explained earlier in this thesis, the quality of the prostate biopsy was described as either 
adequate or inadequate. All biopsies were divided into one of these two groups and further 
statistical analyses were performed.  
5.8.1 Assessing the Number of adequate prostate biopsies 
The first priority was to evaluate how many preoperative biopsies could be defined as being 
“adequate” according to the criteria described in Section 4.4.  
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Table 27. Number of Adequate Prostate Biopsies 
 Number of biopsies Percentage 
Adequate 449 52.4% 
Inadequate 408 47.6% 
Total 857 100% 
 
5.8.2 The influence of the quality of the biopsy on the positive surgical margin rate 
The next analysis of interest was the determination of whether a preoperative prostate biopsy 
of poor quality could negatively influence the positive surgical margin rate. The positive surgical 
margin rate in preoperative biopsies which were considered adequate, was compared to that of 
biopsies of which the quality thereof was considered inadequate, with the following results:  
 
Table 28.The Positive Surgical Margin Rate as influenced by the Biopsy Quality 
 
Positive surgical margin  
Negative Positive Total 
Biopsy Adequate Amount 422 27 449 
  Percentage 94% 6% 100% 
 Inadequate Amount 367 41 408 
  Percentage 90% 10% 100% 
Total   789 68 857 
   92.1% 7.9% 100% 
 
Pearson’s Correlation Test 4.766 
Fisher Exact Test 0.032 
 
The above table demonstrates that there is a statistically significant increase in the positive 
surgical margin rate when the surgeon does not have adequate preoperative information 
concerning tumour localisation and tumour volume. 
 
56 
5.8.3 The Positive Surgical Margin Rate as influenced by the Quality of the Biopsy in a 
Nerve-sparing and a non Nerve-sparing Procedure 
The decision to perform a nerve-sparing operation or not depends on numerous variables of 
which one of the most important is the result of the preoperative biopsy of the prostate. A 
nerve-sparing procedure will only be considered where the pre-operative biopsy reveals a very 
low tumour volume. The aim of the following analysis was to identify whether an inadequate 
preoperative biopsy would influence the positive surgical margin rate in either or both the non 
nerve-sparing and nerve-sparing procedures.  
 
Table 29. The Positive Surgical Margin Rate as influenced by the Biopsy Quality and a non 
Nerve-sparing Operation 
Non Nerve-sparing 
Positive surgical margin  
Negative Positive Total 
Biopsy Adequate Amount 173 9 182 
  Percentage 95,1% 4,9% 100% 
 Inadequate Amount 126 3 129 
  Percentage 97,7% 2,3% 100% 
Total   399 12 311 
   96,1% 3,9% 100% 
 
Pearson’s Correlation Test 1,396 
Fisher Exact Test 0,190 
 
Patients with a preoperative biopsy of adequate quality have a higher positive surgical margin 
rate than biopsies of inadequate quality, but this difference is not statistically significant.  
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Table 30. The Positive Surgical Margin Rate as influenced by the Biopsy Quality and a Nerve-
sparing Operation 
Nerve-sparing 
Positive surgical margin  
Negative Positive Total 
Biopsy Adequate Amount 249 18 267 
  Percentage 93,3% 6,7% 100% 
 Inadequate Amount 241 38 279 
  Percentage 86,4% 13,6% 100% 
Total   490 56 546 
   89,7% 10,3% 100% 
 
Pearson’s Correlation Test 7.013 
Fisher Exact Test 0.006 
 
A statistically significant impact was observed in cases where a nerve-sparing procedure is 
performed in a patient with a pre-operative prostate biopsy of inadequate quality. The relative 
risk increase is 2.03 (13,6%/6,8%).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Positive Surgical Margin distribution depending on quality of biopsy 
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5.9 The preoperative PSA value as a risk factor for positive surgical margins 
 
The positive surgical margin rate was calculated in relation to the PSA value on the basis of the 
theory that an elevated tumour volume is associated with a higher PSA value, even in organ-
confined prostate cancer. The patients were divided into three categories dependent on their 
PSA value. Category 1 was confined to PSA values of below 6ng/ml, Category 2 to between 
6ng/ml and 10ng/ml and Category 3 to values above 10ng/ml. The PSA values used in this 
calculation were those obtained at diagnosis and before any form of hormonal treatment.  
 
Table 31. The Positive Surgical Margin Rate as per PSA Category 
 
Positive surgical margin  
Negative Positive Total 
PSA Category 1 Amount 411 28 438 
 <6ng/ml Percentage 93.6% 6.4% 100% 
 Category 2 Amount 239 23 262 
 6-10ng/ml Percentage 91.2% 8.8% 100% 
 Category 3 Amount 139 17 156 
 >10ng/ml Percentage 89.1% 10.9% 100% 
Total   789 68 857 
   92.1% 7.9% 100% 
 
Pearson’s Correlation Test 3.586 
Fisher Exact Test 0.159 
 
The results demonstrate that there is no statistically significant increase in the positive surgical 
margin rate the higher the PSA value. 
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Figure 11. Positive Surgical Margin Rate according to PSA (ng/ml) 
 
5.10 Multivariable analysis 
 
The above-calculated results were used to perform a multivariable analysis in order to 
determine which factors were independent risk factors for an increased positive surgical margin 
rate in patients with pT2 tumours. The three variables included in this analysis were the nerve-
sparing operation, a low prostate weight (under 35g) and the quality of the preoperative 
prostate biopsy.  
 
Table 32. Multivariable Analysis 
 
Regression Co-
efficient 
Wald Chi Quadrant Significance 
Biopsy Quality -0.398 2.267 0.133 
Nerve-sparing 0.967 8.648 0.003 
Prostate Weight -0.707 5.259 0.022 
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Table 33. Multivariable Analysis and Confidence Interval  
 95% Confidence Interval 
 Exp (B) Lower Value Upper Value 
Biopsy Quality 1.672 0.400 1.128 
Nerve-sparing 2.630 1.381 5.009 
Prostate Weight 0.493 0.270 0.902 
 
The two factors that were proven to be independent risk factors for positive surgical margins 
were a nerve-sparing operation and a low prostatic weight. 
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6. Discussion 
6.1 The Importance of Positive Surgical Margins and their Relation to Surgical 
Technique  
 
Positive surgical margins in organ-confined prostate cancer result in an increased risk of 
biochemical failure as well as tumour recurrence.(62) A study conducted in Hamburg evaluated 
such risk in 4490 patients who had undergone a radical prostatectomy. When positive surgical 
margins were present the five-year risk of a biochemical remission-free increased from 12% to 
18%. In pT2 tumours alone the five-year biochemical remission free rate decreased from 95% to 
83%. The relative risk increase for a biochemical remission in pT2 tumours in the presence of 
positive surgical margins was 2,9. The biochemical prognosis of a patient with a pT2 tumour 
and positive surgical margins is worse than that of pT3a tumour stage and negative surgical 
margins.(63) The overall PSM rate in the study, which is the subject matter of this thesis, was 
7.9%. In other centres where RARP is performed, the PSM rate for organ-confined tumours 
resembled our own and ranged from 9.4% to 14%.(64, 65, 66)  
 
Several studies have compared the results of the RRP to those of the RARP. Most studies, 
however, do not demonstrate a clear advantage of the RARP with regard to the positive surgical 
margins rate in pT2 tumours. 
 
Table 34. Studies comparing the Positive Surgical Margin Rate of the RRP to the RARP in organ-
confined cancer 
 RRP PSM(%) RARP PSM(%) 
Smith et al (2007)(64) 24.1 9.4 
Weizer et al (2010)(65) 12 14 
Laurila et al (2009)(66) 14 13 
 
However, of importance is that high volume urological centres usually publish the data 
mentioned above and not the community hospitals. In an independent report, compiled by 
Cancer Care Ontario, 1346 pathologists’ reports were evaluated in 2005 and 2006. Irrespective 
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of surgical technique the overall pT2 positive surgical margin rate in 43 different hospitals was 
33%.(67) 
 
6.2 Staging, the preoperative PSA and the localisation of the Positive Surgical Margin 
 
Most radical prostatectomies are performed on patients with a pT2 tumour stage, as this 
tumour stage can be cured if treated surgically. The data in this study mirrors that of 
international centres as 71,4% of the 1200 patients that were operated had a pT2 tumour, 
furthermore the pT2c tumour stage was the most common amongst the pT2 tumours.(68) 
 
In this study, an increase in the PSA value was not associated with a statistically significant 
increase in the PSM rate. Other studies have shown that an increased PSA can lead to a higher 
rate of positive surgical margins, however those studies are not specific to organ-confined 
tumours.(51, 69) The examination of organ-confined prostate cancer only, did not reveal an 
association between an elevated PSA level and an increased risk of biochemical recurrence. 
However, the relationship between a positive surgical margin and the PSA was not 
examined.(70) 
 
In nearly 60% of the patients in this study, the positive surgical margin was found at the apex. 
The second highest incidence, almost 30%, was situated basally. Positive surgical margins were 
rarely found in the other locations. Irrespective of surgical technique, most other studies have 
also found the apex to be the most common location for a positive surgical margin.(52, 71, 72) 
  
The relationship between the localisation of the positive surgical margin and a nerve-sparing 
operation was also evaluated in this study. Patients without a nerve-sparing operation had an 
apical positive surgical margin in 83.3% of the time and a basal positive surgical margin in 8.3% 
of the time. In comparison, patients who had had a nerve-sparing prostatectomy had an apical 
positive margin rate of 53.6% and basal positive surgical margin rate of 32.1%. The difference 
between these two population groups was not statistically significant (p=0.176). Marchetti et al 
described patients who had undergone a RARP with a bilateral nerve-sparing operation. The 
overall localisation of the positive surgical margin, irrespective of pathological stage, was 
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posterolateral in 43%, apical in 39% and basal in 17% of patients. Unfortunately no comparison 
could be made to patients who had not undergone a nerve-sparing procedure.(73) 
 
6.3 Positive Surgical Margins and the Nerve-sparing Operation   
 
In this study, the nerve-sparing operation was associated with an increase in the PSM rate from 
3.8% to 10.3%, which was statistically significant. 
 
Research conducted of large databases (Budäus et al.(63), Nelles et al.(74)) have, when not 
taking the surgical technique and tumour stage have not been taken into account, have not 
found a correlation between the positive surgical margin rate and the nerve-sparing operation. 
When organ-confined tumours in RRP patients were examined however, Ahyai et al found a 
statistically significant increase from 7.8% to 13.9% in the positive surgical margin rate when a 
nerve-sparing procedure was performed.(75) With regard to the RARP, Liss et al found an 
increase in the rate of positive surgical margins from 3.3% to 5.9% when a nerve-sparing 
operation was performed. However this was not statistically significant, nor specific for pT2 
tumours.(76) Coelho et al examined 876 patients who had undergone a RARP by a single 
surgeon who had already had the experience of operating more than 1500 cases. He found 
amongst the pT2 tumours the positive surgical margin rate for patients that had not had a 
nerve-sparing procedure to be 8.51%, patients who had received a bilateral nerve-sparing 
operation had a positive surgical margin rate of 8.15% and patients who had received a 
unilateral nerve-sparing operation had a positive surgical margin rate of 6.14%. These values 
were not statistically significant.(77) 
 
Furthermore the analysis in this study revealed that a unilateral nerve-sparing procedure had a 
positive surgical margin rate of 6.8% and a bilateral nerve-sparing procedure a positive surgical 
margin rate of 12.3%. This difference is statistically significant, with p=0.042.  
 
As stated previously, the only study that used the same criteria as this study to evaluate the 
RARP group, namely by Coehlo et al, could not find a statistical difference in the positive 
surgical margin rate after a unilateral or bilateral nerve-sparing operation.(77) Although Greco 
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et al found that when examining patients, with pT2 tumours, who had undergone a 
Laparoscopic radical Prostatectomy (LRP) the positive surgical margin rate rose from 5.3% to 
8.2% when a bilateral instead of a unilateral nerve-sparing procedure was performed. However, 
this difference was once again not statistically significant.(78) 
 
6.4 Prostate Weight 
 
The average prostate weight for a pT2 tumour stage operated by means of a RARP at the 
University Clinic of Saarland was 55.8g, with the median prostate weight being 52g. 
Independently of tumour stage the average prostate weight, in an article published by Zorn et 
al describing 375 patients that had undergone a RARP, was 51.8g.(79) In a study by Msezane et 
al the average prostate weight of 709 patients who had had a RARP was 52.9g.(80)  
 
When the RARP program was first introduced in the University Clinic of Saarland, patients with 
larger prostates (>60g) where excluded from the initial surgeries as it was thought that a larger 
prostate would lead to more difficult intra-operative conditions. This exclusion criterion was, 
however, lifted after 10 operations.(81) Conversely other studies have shown that a low 
prostate weight in RRP specimens is associated with an increase the positive surgical margins 
rate.(82) It was for this reason that prostate weight in patients undergoing a RARP was also 
investigated in this study. Due to the large number of patients in this study, six distinct weight 
categories were established: ≤35g, 35.1-45g, 45.1-55g, 55.1-65g, 65.1-75g and >75g. The 
prostate weight did have an impact on the positive surgical margin rate (p=0.045). This was 
especially true when patients with a very low prostate weight (≤35g) were compared to the rest 
of the population in the cohort (14.9% vs 6.9%, p= 0.008). The overall relative risk increase for a 
positive surgical margin when a patient has a low prostate weight is 2.1. 
 
In his 2007 article, Zorn et al showed similar trends with patients who had undergone a RARP 
for pT2 tumours. He found that the prostate weight group of less than 50g had a significantly 
increased risk of having a positive surgical margin.(79) Another study, conducted by Skolarus et 
al evaluated 885 patients who had undergone a RARP were evaluated for positive surgical 
margins. Irrespective of the tumour stage the patients were divided into three groups according 
65 
to the prostate weight. The first category was that of patients with a prostate weight of less 
than 50g, the second of between 50g and 100g and the third category encompassed patients 
who had a prostate weight of more than 100g. The positive surgical margin rate was 19%, 
11,1% and 0%, respectively.(83) Ficarro et al also demonstrated in 2009 that in his evaluation of 
preoperative risk factors for positive surgical margins in patients undergoing a RARP, that a 
prostate volume of less than 40cc was a risk factor for an increased incidence of positive 
surgical margins.(84) A similar study conducted by Frota et al in patients undergoing a LRP were 
divided into three groups depending on the prostate weight: under 30g, between 30g and 75g 
and above 75g. The positive surgical margin rate was 39%, 16% and 27% respectively.(85) The 
results found in the fore-mentioned study were confirmed in another study where patients 
who underwent a RRP, had a higher positive surgical margin rate the smaller the prostate 
weight, irrespective of pathological stage: 14% if <40g, 12% for 41g-50g, 10% for 51g-65g and 
10% for >65g respectively. These figures were statistically significant.(86) In a study examining 
the biochemical recurrence rate of pT2 tumours Cho et al noted that a low prostate volume of 
under 30g was associated with an increased risk of biochemical recurrence. Unfortunately the 
positive surgical margin rate was not calculated in Cho’s study.(87) 
 
Although the authors of a recent publication recommended that the prostate specimen should 
be used as the preferred method of measuring prostate size in prostatectomy studies,(88) the 
question arises whether the postoperative prostate weight can adequately be determined pre-
operatively. It has been proven that prostate volume can be equated to prostate weight where 
the seminal vesicles have been removed.(89) Preoperatively most urologists depend on 
transrectal ultrasound, the accuracy of which is operator dependent.  
 
In this study at the University Clinic of Saarland, the effect of the combination of a low prostate 
weight and a nerve-sparing operation was examined. The patients were divided into two 
categories, those who had not had a nerve-sparing operation and those who had. Examination 
of the prostate weight in the cases of non nerve-sparing operations revealed no statistical 
correlation between the non nerve-sparing and the positive surgical margin rate. In the weight 
category less than or equal to 35g and above 35g, the positive surgical margin rate was 3.2% 
and 3.9% respectively, with p = 1.000. Evaluation of the nerve-sparing procedures over all the 
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weight categories, did not reveal any statistically significant difference when it came to the 
positive surgical margin rate (p = 0.081). However, when a comparison was made between 
patients with a nerve-sparing operation and a prostate weight of less than or equal to 35g, 
compared to that of above 35g, the positive surgical margin rate was 19.3% and 8.7% 
respectively, with p = 0.009. This demonstrates that nearly 20% of all patients who undergo a 
nerve-sparing operation with a low prostate weight and an organ-confined tumour will have a 
positive surgical margin. 
 
Studies demonstrating this exact correlation could not be found, but a study by Marchetti et al, 
that examined organ-confined tumours and a bilateral nerve-sparing procedure demonstrated 
that the predicted probability of a positive surgical margin of a prostate of 25g, 50g, 100g and 
150g was 22%, 13%, 5% and 1% respectively.(73) 
 
6.5 The Quality of the Preoperative Prostate Biopsy 
 
The diagnosis of prostate cancer is usually made on a prostate biopsy. Indications for a prostate 
biopsy are usually found on the digital rectal examination as well as on the raised PSA level in 
serum. Other factors, which may indicate that a prostate biopsy is required, are the free/total 
PSA ratio and the PCA3 marker, although these are rarely used as independent screening tools. 
Once the decision has been made to perform a prostate biopsy, two methods can be used, 
either a transrectally guided biopsy or a perineal biopsy. According to the European Association 
of Urology (EAU) both methods have similar cancer detection rates, although most urologist 
prefers the transrectal approach. Certain guidelines should be adhered to while taking the 
biopsies: 
 The sample site should be as far posterior and lateral in the peripheral zone as possible 
 Additional cores should be removed from the areas of suspicion  
 Prostate glands with volumes of 30-40ml, should have at least 8 cores removed 
 There does not seem to be a benefit to removing more than 12 cores(20) 
According to the British Prostate Testing for Cancer and Treatment Study Group, when testing 
for prostate cancer, 10 cores should be removed for an accurate diagnosis.(90) 
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On the basis of aforesaid, it was decided in this study that the quality of the preoperative 
prostate biopsies of the patients operated upon at the University Clinic of Saarland were to be 
examined in the light of whether they were of assistance in properly preparing the surgeon for 
the operation. This unit retrospectively used two criteria to determine whether the biopsy was 
of adequate quality:  
 The biopsy should comprise of at least eight cores 
 The location of the positive biopsy core should be stipulated 
This information was also used to decide whether a nerve-sparing procedure should be 
performed, either unilaterally or bilaterally, or whether it was in the patient’s best interests to 
abstain from a nerve-sparing procedure. The aim is to have as much information as needed 
about the tumour burden and location of the tumour in any given prostate lobe. According to 
this criteria 52.4% of the patients had an adequate prostate biopsy and 47.6% had an 
inadequate prostate biopsy. 
 
Whereas the positive surgical margin rate was found to be 6% in cases where an adequate 
biopsy was taken, in cases of an inadequate prostate biopsy, it rose to 10%, which was 
statistically significant, with p = 0.032. Several different studies regarding prostate biopsies 
have been conducted although few attempt to identify the quality of the biopsy. Frota et al 
conducted a study comparing the prostate biopsies that were positive for cancer and the final 
pathology after radical laparoscopic prostatectomy. In his study, the average amount of cores 
removed was 10.3 (6-24). However, he found that the correlation between the preoperative 
biopsy results and the final pathology was very poor. Only 37% of the patients had a positive 
prostate biopsy bilaterally, whereas on the final specimen 86% of the patients had cancer 
bilaterally and 58% of them had significant cancer bilaterally. The positive surgical margin rate 
did also not relate to the positive biopsy cores. In patients with positive biopsy results in the 
right lobe only, the contralateral (left) lobe had positive surgical margins in 10% of the cases, 
extracapsular extension in 11% and significant cancer in 5%. The same assessment was 
performed on patients who had a positive biopsy in the left lobe only, who on final pathology 
also showed in the contralateral (right) lobe positive surgical margins in 12% of the cases, 
extracapsular extension in 8% and significant cancer in 7%. In 24% of the patients only six 
needle core biopsies were taken, in 63% of the patients 7-12 needle core biopsies were taken 
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and in 13% of the patients more than 12 needle core biopsies were taken. Unfortunately, 
however no correlations were drawn between the amount of preoperative biopsies and the 
positive surgical margin rate.(91) In a similar study Bulbul et al also showed that 66% of patients 
who had unilateral disease on prostate biopsy had in fact bilateral disease on the final 
pathological specimen.(92) Sfakianos et al suggests that the amount of biopsies taken should be 
decided by the size of the prostate. In his study the prostate volume to biopsy core ratio 
(volume/number of cores) was calculated. It was found that the median prostate 
volume/number of cores was 3.5 in patients diagnosed with prostate cancer whereas those 
who were not diagnosed with cancer had a ratio of 4.7, the difference being statistically 
significant. It was therefore suggested that the prostate cancer detection could be enhanced by 
reducing the ratio between prostate volume and the number of core biopsies taken, i.e. the 
larger the prostate, the more cores should be removed.(93) Hashimoto et al also proved the 
relationship between the percentage of positive core biopsies and the rate of positive surgical 
margins. If more than 35% of the biopsies were involved with cancer, there was a statistically 
significant increase in the positive surgical margin rate, emphasising the importance of good 
preoperative biopsies.(69) 
 
In this study as far as the nerve-sparing procedure is concerned, those patients who had had 
adequate preoperative prostate biopsies had a positive surgical margin rate of 6.7%, whereas 
those who had not, had a positive surgical margin rate of 13.6%. This difference was statistically 
significant, p = 0.006. This difference was not found when non nerve-sparing operation was 
performed. This result indicates that where the surgeon has inadequate preoperative 
information and a nerve-sparing procedure is performed, the patient has a worse oncological 
outcome. This leads us to conclude that a standardised, international biopsy method is 
essential and that if it has not been adhered to, a nerve-sparing procedure should be 
reconsidered. 
 
6.6 The Learning Curve of the pT2 Tumours 
 
The learning curve of the pT2 tumours over time was evaluated. As stated in the beginning of 
this thesis 1200 patients were evaluated in this study, although only 857 had a pT2 tumour. The 
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1200 patients were divided into three equal groups of 400 patients each and the learning curve 
of the pT2 tumours was evaluated for each group of 400 patients. Of importance was that over 
time the number of patients with a pT2 tumour per 400 patients decreased steadily form 306, 
to 297 to 254. During this same period of time there was a steady increase in the number of 
patients with pT3 tumours who were treated surgically. This trend was, however, not 
statistically significant. 
 
Another variable that was analysed over time was the amount of nerve-sparing operations that 
were performed in pT2 tumours. In the first 400 patients 75.8% of all patients with a pT2 
tumour received a nerve-sparing operation. In the next 400 patients only 62.3% received a 
nerve-sparing operation and in the last 400, only 50.8% had undergone an nerve-sparing 
operation, thus showing a steady decline in the number of patients receiving this procedure (p 
< 0.0001). The nerve-sparing procedure became a more selected procedure over time. We 
know from previous calculations that this procedure has a statistically significant increased risk 
of contributing to positive surgical margins. Unfortunately, to our knowledge no literature could 
be found analysing the trend in nerve-sparing operations over time. 
 
Furthermore the learning curve with regard to the positive surgical margin over time in pT2 
tumours was analysed. This analysis delivered the following results: the positive surgical margin 
rate in the first category of 400 patients, of whom 307 had a pT2 tumour was 12.1%. In the next 
400 patients, of whom 297 had a pT2 tumour, the positive surgical margin rate was 6,1% and in 
the last 400 patients, of whom 254 had a pT2 tumour, the positive surgical margin rate was only 
5.1%, giving an average rate of 7.9%. The decrease in the positive surgical margin rate was 
statistically significant with p = 0.003. 
 
Learning curves and benefits of surgical volumes can usually be demonstrated in all surgical 
modalities. This was shown by Chun et al who examined the positive surgical margin rate 
depending on surgical volume for RRPs. One surgeon who had performed 1293 RRP’s was 
compared to 10 other surgeons who had operated between 1 and 237 open radical 
prostatectomies. The positive surgical margin rate for the experienced surgeon was 20.2%, 
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whereas the positive surgical margin rate for the remaining surgeons was 22.6% the difference 
being statistically significant.(94) 
 
Often in contemporary literature a new surgical technique is critisized for “sacrificing the initial 
patients during the learning curve”, since these early cases often do have a worse oncological 
outcome than if they were operated by a more conventional surgical technique. As far back as 
2009, White et al compared the postitve surgical margins of patients undergoing either a RRP 
or a RARP at a single center, operated upon by a single urologist during the initiation stage of a 
robotics programme. In total 63 patients underwent a RRP and 50 a RARP. The positive surgical 
margin rate was 36% in the RRP group and 22% in the RARP group. When only the pT2c 
tumours cases were examined the positive surgical margin rate in the RRP group was 42.8% and 
22.8% in the RARP group, demonstrating that even in the initial phase RARP does not have a 
higher positive surgical margin rate.(95) Rocco et al also compared 120 patients who had 
undergone an RARP to a historical control group of consecutive patients who had undergone an 
RRP. The positive surgical margin rate for the RARP group was 22% and for the RRP group 25%, 
respectively. There was no statistically significant difference. When only the pT2 tumours were 
evaluated 15% in the RARP group and 17% in the RRP group had positive surgical margins, once 
again not demonstrating a statistically significant difference.(96) 
 
Studies examing the experience in a surgical technique have also been conducted 
demonstrating once again that the more experience one has in a surgical technique, the less 
positive surgical margins are present. The results of surgeons performing a RARP who either 
have experience in the robotic surgery or laparoscopic surgery (LRP) have been compared in 
their rate of positive surgical margins. In total 286 operations were performed; 121 by surgeons 
experienced in RARP and 165 by surgeons experienced in LRP. The positive surgical margin rate 
for the surgeons experienced in LRP was 34.6%, whereas those experienced in RARP had a 
positive surgical margin rate of 24.0%, which was statistically significant. Unfortunately this 
difference could not be replicated when the results of surgery on pT2 tumours were analysed, 
but none-the-less the overriding conclusion is that experience in a surgical technique does lead 
to better results.(97) 
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Atug et al examined the learning curve in RARP in a small group of patients. The first 100 
patients who had undergone a RARP by the same surgical team were evaluated for the learning 
curve, with focus on the positive surgical margin rate. The patients were divided into three 
groups of 33,33 and 34 patients respectively. The overall positive surgical margin rate declined 
from 45.4%, to 21.2% to 11.7%. When the positive surgical margin rate of patients with a pT2 
tumour stage only were evaluated, the positive surgical margin rate was as follows: 38.4%, 
13.7% and 3.6% respectively. The analysis was performed on a very small group of patients, but 
the difference was statistically significant (p=0.0035).(98) Liss et al published one of the few 
articles about RARP with contradicting results. Of the first 216 patients that were operated via a 
RARP as well as over the first 149 that had a pT2 tumour stage, no decrease in the positive 
surgical margin rate could be seen (p=0.371). There was, however, a statistically significant 
decrease in the positive surgical margin rate for pT3 tumours.(76) 
 
In total it is however safe to say that there seems to be a very short learning curve with regard 
to the RARP.  
 
Furthermore, in this study the positive surgical margin rate of the patients who had undergone 
a nerve-sparing operation and a non nerve-sparing operation were also evaluated. Where 
patients who had not had a nerve-sparing procedure were concerned, the positive surgical 
margin rate varied from between 4.1%, 2.7% and 4.8% in the three groups respectively. No 
clear trend could be established and no statistical significance could be drawn from this 
information. The 546 patients who had undergone a nerve-sparing procedure were also 
evaluated over time. In total 232 patients had received a nerve-sparing procedure in the first 
400 patients, 185 in the next 400 patients and 129 patients had received a nerve-sparing 
procedure in the last 400 patients. The positive surgical margin rate was 14.7%, 8.9% and 5.4% 
respectively, thus demonstrating a statistically significant  decline in the positive surgical margin 
rate over time in patients undergoing a nerve-sparing procedure. It can therefore be said that 
the positive surgical margin rate of patients who do not undergo a nerve-sparing procedure 
remains stable and that there is no learning curve. The true learning curve over time is reflected 
in the nerve-sparing procedure (p = 0.011). Unfortunately no literature could be found where  
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the positive surgical margin rate over time in patients who have undergone a nerve-sparing 
procedure were evaluated.  
 
6.7 Multivariable analysis 
 
The multivariable analysis was used in this study assess the variables that are significant in the 
prediction of positive surgical margins in patients with organ-confined prostate cancer who 
undergo a RARP. The reasoning behind the use of this analysis was to identify patients who are 
at risk of having positive surgical margins, at the preoperative stage already. Three variables 
were identified as being of current importance: the nerve-sparing operation, a low prostate 
weight (less than or equal to 35g) and the quality of the preoperative biopsy. A regression 
analysis was used to evaluate these three parameters along with the Wald test. Only two of the 
variables were statistically significant: the nerve-sparing operation and the prostate weight 
(p=0.003 and p=0.022 respectively). The confidence interval for all three variables was 
calculated, with a 95% confidence interval for the nerve-sparing operation from 1.381 to 5.009 
and the prostate weight from 0.270 to 0.902, respectively. 
 
With the above given information we can confidently say that men with a low prostate weight 
of less than 35g and men undergoing a nerve-sparing operation are at increased risk of having 
positive surgical margins in organ-confined prostate cancer.  
 
6.8 Limitations of this Study 
 
This study has a few limitations. One of them would be the identification of which men have 
organ-confined disease prior to surgery. Unfortunately only an educated guess may be 
ventured, although there are a number of tools to guide the clinician, such as the digital rectal 
examination, a PSA of less than 10ng/ml and the D’Amico risk stratification which groups 
patients into low, intermediate and high risk categories. Although this risk stratification is not 
failsafe, in a study by Hernandez et al, the five-year biochemical recurrence-free survival for the 
low, intermediate and high-risk groups according to D’Amico’s criteria were 94.5%, 76.6% and 
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54.6% respectively, thereby providing the relevance of such a risk stratification process.(99) 
Ideally normograms should be designed that accurately predict organ-confined disease based 
on preoperative information. In one such a study by Huang et al, the 2007 Partin Tabels model 
was used to design the „Partin Normogram“ to try and predict just that. Based on the patient’s 
preoperative clinical stage, the tPSA and the biopsy Gleason Score, Huang’s study attempted to 
predict organ-confined disease, extracapsular extension, seminal vesicle invasion and positive 
lymph node disease. The aim of the study group is to design a computer programme to 
facilitate these predictions.(100) Despite this and other studies, a 100% accurate prediction will 
never be possible when it comes to identifying patients who only have organ-confined cancer.  
 
Another limitation is that although prostate volume and prostate weight can be equated 
postoperatively (89) (as previously discussed) an accurate preoperative prostate volume cannot 
always be determined accurately. Most patients who undergo a radical prostatectomy will have 
their prostate volume measured by transrectal ultrasound at time of the biopsy. As we know, 
sonographic measurements are very operator dependent. In a study conducted by Nunaz-
Nateras et al the preoperative prostate volume of 302 patients was measured by a group of 
urologists and radiologists. The preoperative volume was than compared to the postoperative 
prostate volume after RARP. It was found that the preoperative measurement was within 17%-
22% of the postoperative weight, thus demonstrating that a preoperative ultrasound is a 
relatively good estimate of the postoperative volume.(101) Unfortunately not all ultrasound 
operators work as accurately as the aforementioned and instead of advocating an absolute cut 
off value of 35g, which was the statistically proven value in this study, it would be more realistic 
to caution surgeons about patients with low prostate weights of approximately 35g.  
 
This University Clinic of Saarland study proves that patients with organ-confined disease 
undergoing a nerve-sparing operation and patients with organ-confined disease and a low 
prostate weight are at greater risk of positive surgical margins than other patients when a 
robotic-assisted radical prostatectomy is performed.   
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9. Abbreviations 
 
 
EAU European Association of Urology 
 
ERBT External Beam Radiation Therapy 
 
LRP Laparoscopic Radical Prostatectomy 
 
PSM Positive Surgical Margin 
 
PSA Prostate Specific Antigen 
 
RARP Robotic-assisted Radical Prostatectomy 
 
RRP  Retropubic Radical Prostatectomy 
 
R0  Negative surgical margins 
 
R1 Positive surgical margins  
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11. Attachments 
Da Vinci Laufzettel 
 
Patientenaufkleber 
 
Patienten Daten 
Alter  Aufnahme Datum  
Aufgenommen durch  Überwiesen 
durch 
 
Präoperative Arbeit  
0 = Nein 
1 = Ja 
 Arbeit 
1=selbstständig, 
2=angestellt 
 
 
Prätherapeutische Daten 
Komorbidität  
Vordiagnosen  
Voroperationen     
Gewicht (kg)  BMI  
Grösse (cm)  
ASA  NYHC  
Präop Hb  Präop Hkt  
Präop CRP    
Antikoagulation 0=nein               
1=Marcumar        2=ASS           
3=Plavix         4=Heparin        
5=andere 
Antik. Pausiert (d)  
 
Inzidentelles 
Prostatakarzinom 
0=nein         1=pT1a (<5%)    
2=pT1b (>5%) 
 
Präop. Stanze 1=bei uns       
2=auswärts 
Anzahl Stanzen  
Anzahl pos. Stanzen li  Anzahl pos. re  
Präop Gleason  Präop Gleason 
Score 
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Datum Stanze  
Skelett Szinti 0=nein  
1=positiv  2=negativ 
 
Präop TNM  
PSA präop  PSA bei 
Diagnosestellung 
(neoadjuvant 
therapierte 
Patienten) 
 
Vorbehandlung 0=Nein 
1=LHRH  2= perpheres 
Antiandrogen  3= 
perpheres Antiandrogen 
(steroidal) 4= 5α 
Reduktasehemmer  
5=Chemotherapie  
6=Brachytherapie  
7=andere 
 Dauer (Monate)  
 
TRUS  
Prostata Volumen  Adenom Volumen  
Echoarmer Bereich  
0=nein  1=rechts  2=links  
3=beide 
 Kapseldurchbruch  
0=nein  1=rechts  
2=links  3=beide 
 
SB dilatiert 0=nein  
3=rechts  2= links  3=beide 
 SB infiltriert  
0=nein  1=rechts  
2=links  3=beide 
 
Tastbefund suspekt  
0 = Nein 1=ja 
 
 
Präop. Kontinenz 
0=nein 1=ja 
 Präop. Potenz           
0=nein 1=ja 
 
IIEF Score  ICSSF Score  
QLQ 30    
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Operation 
OP Datum  Operateur 
1=Stöckle   
2=Siemer    
3=Kamradt  
4=Gerber  
5=Becker  
6=Ohlmann 
7=Kopper 
8=Akcetin 
 
OP-Zeit (Schnitt-Naht) 
[Min.] 
 Blutverlust (ml)  
Nervsparing  0=nein      
1=ja 
Nervsparing 
1=rechts    2=links       
3=beidseits 
 
Erhalt der 
puboprostatischen 
Bänder mit anteriorer 
Präparation des/der 
neurovaskulären 
Bündel 0=Nein 1=Ja   
 
Rocco Anastomose  
0= Nein 1= Ja 
 
Postop Hb (5 Tag)  Postob Hkt  
CRP  
Komplikationen 
(intraoperativ) 
 0=nein 1=ja 
 Konversion   
0=nein         1=ja 
Technisches 
Problem        2=ja 
OP Problem 
 
Ableitung 
1=BK, 2=BK und Zystofix, 
3=nur Zystofix 
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Histologische Daten 
Prostatavol. (ml)    
pT  pN  
Anzahl entfernten 
Lymphknoten 
 Anzahl 
tumorokupierte 
Lymphknoten 
 
M  
postoperativer Gleason   postop. Gleason-
Score 
 
R     0=R0    1=R1    2=R2  R           1=basal  
2=lateral 3=apikal   
4=Samenblase 
5=Ductus 
 
R           1=fokal   
2=ausgedehnt 
 
 
 
Postoperative Daten 
Entlassungstag Datum  
Blasenkatheterentferung 
Datum 
 
Entlassung 0=ohne 
Ableitung, 1= mit Zystofix, 2= 
mit BK, 3=mit BK und 
Zystofix 
 Grund f. längere 
Katheterdauer 1= 
Paravasat, 2= Andere 
(Erklären) 
 
Zystofixentferung Datum    
Kontinenz       1=gute 
Frühkontinenz  
2=mäßige/schlechte 
Kontinenz 
 Anzahl  Pads 
gebraucht in erste 
24h nach 
Katheter Ex 
 
Komplikationen 
(postoperativ)      0=nein 
1=ja (Welche?) 
 Komplikation 
Grad (1-5) 
 
 
 
Besonderheiten  
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